{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "%matplotlib inline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import torch\n",
    "import json\n",
    "from collections import defaultdict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "with open('./BioASQ-trainingDataset5b.txt', encoding='utf8') as f:\n",
    "    data = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "defaultdict(int, {'factoid': 486, 'list': 413, 'summary': 400, 'yesno': 500})"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "question_type = defaultdict(int)\n",
    "for sample in data['questions']:\n",
    "    question_type[sample['type']] += 1\n",
    "question_type"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Exact answer case study"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['TH monocarboxylate transporter 8 (MCT8) mutation is implicated in the TH resistance syndrome']\n",
      "[['Bazex syndrome']]\n",
      "[['castration-resistant prostate cancer']]\n",
      "[['glycosyltransferase 8 domain containing 1']]\n",
      "[['plasma membrane']]\n",
      "['autosomal recessive']\n",
      "['autosomal dominant']\n",
      "[['Hydrophilic Interaction Chromatography']]\n",
      "[['All-alpha-helical fold']]\n",
      "[['c-Jun NH2-terminal kinase', 'JNK']]\n",
      "['TAILS: Terminal Amine Isotopic Labeling of Substrates']\n",
      "[['EWS/FLI1']]\n",
      "[['acute ischemic stroke']]\n",
      "[['proprotein convertase subtilisin/kexin type 9']]\n",
      "['S-adenosyl-L-methionine']\n",
      "[['Hedghog signalling pathway']]\n",
      "[['In Fanconi anemia cells, the S-phase checkpoint is inefficient.']]\n",
      "[['aryl hydrocarbon receptor interacting protein']]\n",
      "[['human telomerase reverse transcriptase']]\n",
      "[['SCF(β-TrCP)', 'SCF beta-transducin repeat-containing protein (beta-TrCP)', 'beta-Trcp']]\n",
      "['No crustal structure of Greek Goat Encephalitis found']\n",
      "[['thyroid transcription factor 1']]\n",
      "['Human Telomerase']\n",
      "[['hormone receptor-positive, human epidermal growth factor receptor 2-negative']]\n",
      "[['proteomic sample preparation']]\n",
      "['cytochrome P450, CYPC19']\n",
      "[['Transcription factor EB (TFEB)']]\n",
      "[['Reverse transcription - polymerase chain reaction (RT-PCR)']]\n",
      "[['The study of protein-protein interactions in a physiologically relevant developing context.']]\n",
      "['Mutations or/and deletions in the genes of the cAMP-response element binding protein-BP (CREBBP) (50-60% of the cases) and of the homologous gene E1A-binding protein (EP300) at 22q13 (5%).']\n",
      "[['stem cell renewal and self-immune tolerance']]\n",
      "['Mutation in NF1 gene.']\n",
      "['Selenoprotein P']\n",
      "[['r3Cseq']]\n",
      "['none', '0', 'zero']\n",
      "[['catechol-O-methyltransferase']]\n",
      "['mostly multiple']\n",
      "[['The molecular genetic basis of spinal muscular atrophy (SMA), an autosomal recessive neuromuscular disorder, is the loss of function of the survival motor neuron gene (SMN1)']]\n",
      "['TBC1D7']\n",
      "[['The calcium/calmodulin-dependent protein kinase-II', 'CaM kinase II', 'CAMK2']]\n",
      "[['dipeptidyl peptidase-4 (DPP-4) inhibitors']]\n",
      "['The mutational status of the IGHV genes.']\n",
      "[['zinc']]\n",
      "[['increased olfactory acuity']]\n",
      "['between 10,000 and 20,000']\n",
      "[['Clostridium botulinum']]\n",
      "[['Spermidine protects against α-synuclein neurotoxicity']]\n",
      "['Centromeres']\n",
      "['Delayed enhancement by CMR has prognostic value in predicting adverse cardiovascular events among HCM patients.']\n",
      "[['mitochondrial intermembrane space']]\n",
      "[['GBshape']]\n",
      "[['E3 ubiquitin ligase activity']]\n",
      "[['Neu5Gc is an immune message to self']]\n",
      "[['CO2', 'bicarbonate']]\n",
      "['Cysteine']\n",
      "['Repressor']\n",
      "[['Aganlionic megacolon or Hirschsprung disease']]\n",
      "[['Fanconi anemia']]\n",
      "[['Orally']]\n",
      "[['Robinow syndrome']]\n",
      "[['poly(ADP-ribose) polymerase', 'PARP']]\n",
      "['sodium glucose co-transporter 2']\n",
      "['There is a relationship between altered thyroid profile and mortality in patients with heart failure']\n",
      "[['the transcribed strand']]\n",
      "[['UUCCUUAAC']]\n",
      "[['Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks']]\n",
      "[['TSC1 and TSC2 genes']]\n",
      "[['Chd1 is an ATP-dependent DNA helicase']]\n",
      "[['NEDD8-activating enzyme']]\n",
      "[['The HS-1 associated protein X-1', '(HAX-1)']]\n",
      "['Between 20,000 and 25,000']\n",
      "['Reduction of number of exacerbations']\n",
      "[['5-aminolevulinic acid']]\n",
      "['9']\n",
      "[['The mouse double minute 2 (mdm2)', 'The human homologue of Mdm2 (Hdm2)']]\n",
      "['Between 1% and 2% ']\n",
      "[['Fusarium oxysporum f. sp. cubense']]\n",
      "[['CD99']]\n",
      "['Tuberous Sclerosis is caused by hyperactivation of the mTOR signalling pathway.']\n",
      "[['There is no clear evidence of the relationship between sweating and anaerobic threshold']]\n",
      "[['signaling lymphocytic activation molecule-F7']]\n",
      "[['β-galactosidase']]\n",
      "[['cerebral hemiatrophy']]\n",
      "[['Tafazzin (TAZ) gene']]\n",
      "['70 genes']\n",
      "['three', '3']\n",
      "['CENPA is preferentially localized in eukaryotic centromeres']\n",
      "['fibroblast growth factor receptor 3 (FGFR3)']\n",
      "['small-cell lung cancer']\n",
      "[['Lantibiotics are post-translationally modified natural peptides containing lanthionine']]\n",
      "['PD-1']\n",
      "[['mDia proteins are members of the formin family']]\n",
      "[['delta-distance']]\n",
      "['Immunoaffinity purification']\n",
      "[['EGFRvIII']]\n",
      "['Non-small cell lung cancer', 'Squamous cell carcinoma']\n",
      "['1:5000']\n",
      "[['The inulinase acts on the beta-(2,1)-D-fructoside links in inulin releasing D-fructose.']]\n",
      "['BCR-ABL']\n",
      "[['2014']]\n",
      "[['Sushi.R']]\n",
      "[[' fewer than 100']]\n",
      "[['late differentiating primary cells']]\n",
      "['CRISPR-Cas']\n",
      "['via mutations in beta-MHC and alpha-TPM1']\n",
      "['hypertrophic cardiomyopathy']\n",
      "['10-28%']\n",
      "[['GAN gene']]\n",
      "['seven', '7']\n",
      "['luminal side of the endoplasmic reticulum']\n",
      "['effective in younger individuals']\n",
      "['Lung']\n",
      "['iron']\n",
      "['Acetylated lysines']\n",
      "[['Three']]\n",
      "['thyroid']\n",
      "[['glutamate receptor ionotropic kainate']]\n",
      "[['Serine 129']]\n",
      "[['Interleukin-17']]\n",
      "[['6-7 kb']]\n",
      "['NF1']\n",
      "['autosomal dominant', 'autosomal recessive']\n",
      "[['Christianson syndrome']]\n",
      "['The lock mass is a compound of known mass and is used to compensate for drifts in instrument calibration.']\n",
      "['cytomegalovirus']\n",
      "[['translocation t(11;22) (q24;12)']]\n",
      "[['To protect c-myc CRD from endonucleolytic attack.']]\n",
      "[['It intercalates into the double helix.']]\n",
      "['alpha-Synuclein']\n",
      "[['lipid inositol phosphatase activity']]\n",
      "['up to > 60%']\n",
      "[['tuberculosis']]\n",
      "[['Situs inversus totalis is a rare congenital anomaly with a complete mirror image of the thoracic and abdominal organs.']]\n",
      "['Diabetes mellitus']\n",
      "[['the carboxyl-terminal Lys-Asp-Glu-Leu (KDEL)']]\n",
      "[['interleukin-5']]\n",
      "[['myoclonic astatic epilepsy']]\n",
      "[['Keratoconus', 'cornea blindness due to severe corneal scarring']]\n",
      "['Japanese encephalitis virus (Flaviviridae) NS5 - PDB:4K6M']\n",
      "['Women']\n",
      "['Methyl-CpG-binding protein 2 (MECP2)']\n",
      "[['14,120 Da']]\n",
      "['glucocerebrosidase']\n",
      "[['Craniosynostosis']]\n",
      "[['LEKTI', 'lymphoepithelial Kazal type-related inhibitor']]\n",
      "[[\"Parkinson's disease (PD)\"]]\n",
      "['Type 1 deiodinase', 'type 3 deiodinase']\n",
      "['Repressor']\n",
      "[['orexin']]\n",
      "[['type 2 diabetes mellitus']]\n",
      "[['6th to 10th week of gestation', 'first trimester of pregnancy']]\n",
      "['longer than the general population']\n",
      "['tofacitinib']\n",
      "[['serotonin clearance']]\n",
      "[['Wnt signaling']]\n",
      "['alpha-galactosidase A']\n",
      "[['The neutrophil elastase gene (ELANE)']]\n",
      "[['To provide comprehensive expression profiles and functional annotation of mammalian cell-type-specific transcriptomes with wide applications in biomedical research.']]\n",
      "['schizophrenia']\n",
      "[['IgG4']]\n",
      "[['riociguat']]\n",
      "[['Single guide RNA is part of the CRISPR/Cas9 system.']]\n",
      "['PI3K-δ', 'phosphoinositol-3 kinase delta isoform']\n",
      "['Valproate']\n",
      "[['Yersinia pestis']]\n",
      "[['1,4-benzothiazepine', 'benzothiazepine']]\n",
      "['upregulated']\n",
      "['Oxantel disrupts polymicrobial biofilm']\n",
      "[['Apelin, a small regulatory peptide, is the endogenous ligand for the apelin receptor (APJ) receptor.']]\n",
      "['PABC4 is important for mRNA stability and translation initiation, in chronic inflammation and in the pathogenesis of colorectal cancer.']\n",
      "[['Nonreceptor tyrosine kinase', 'Protein-Tyrosine Kinase']]\n",
      "['autosomal dominant']\n",
      "['RFX6']\n",
      "[['Alpha-synuclein']]\n",
      "[['Transcription-factor occupancy at HOT regions quantitatively predicts RNA polymerase recruitment.']]\n",
      "[['XRN1']]\n",
      "[['programmed death receptor-1']]\n",
      "[['mitochondrial fission']]\n",
      "[['antagonizes', 'blocks']]\n",
      "[['Multiple myeloma']]\n",
      "[['Flaviviridae']]\n",
      "['Point mutations']\n",
      "[['aortic root dissection']]\n",
      "['autosomal dominant']\n",
      "[['24nm - 25 nm']]\n",
      "[['Protein phosphatase 1', 'PP1']]\n",
      "[['globus pallidus internus']]\n",
      "['autosomal dominant or autosomal recessive']\n",
      "[['EAAT1 mutations']]\n",
      "[['Coordination of the progression of helicase and DNA polymerase alpha at the eukaryotic replication fork.']]\n",
      "['Growth hormone']\n",
      "[['deltaF508']]\n",
      "[['Immune Defence']]\n",
      "[['meningioma']]\n",
      "['centrosome']\n",
      "[['secretory phospholipase A2']]\n",
      "[['SGLT2']]\n",
      "['detection  of myocardial fibrosis in nonischemic cardiomyopathies']\n",
      "[['chaperone-mediated autophagy (CMA)']]\n",
      "['Serine 5']\n",
      "['reducing sodium']\n",
      "[['Norvaline']]\n",
      "[['receptor activator of nuclear factor-κB ligand', 'RANKL']]\n",
      "['spleen tyrosine kinase']\n",
      "['MTM1 gene test']\n",
      "[['epithelial cells']]\n",
      "[['N-terminally']]\n",
      "[['antiganglioside antibody']]\n",
      "[['psoriasis']]\n",
      "['Low T3 syndrome occurs frequently after CABG']\n",
      "[['Spt-Ada-Gcn5-acetyltransferase']]\n",
      "[['Ataxin 2']]\n",
      "[['Viroids']]\n",
      "[['Schistosoma spp']]\n",
      "[['mpMoRFsDB']]\n",
      "[['LepChorionDB']]\n",
      "[['Aurora A']]\n",
      "['Epidermal growth factor receptor (EGFR)']\n",
      "[['At least 15%, based on the International Fanconi Anemia Registry (IFAR)']]\n",
      "['One']\n",
      "[['free fetal DNA from maternal cirulcation']]\n",
      "[['Ecallantide']]\n",
      "[['piggyBac']]\n",
      "['Polycystic kidney disease (PKD)']\n",
      "[['Prostaglandin I(2)']]\n",
      "[['Beta glucocerebrosidase']]\n",
      "[['Medulloblastoma']]\n",
      "['Carboxyl terminus of hsc70-interacting protein (CHIP)']\n",
      "[['Fungi']]\n",
      "[['Batten disease', 'juvenile-onset neuronal ceroid lipofuscinosis', 'JNCL']]\n",
      "['A CAG trinucleotide repeat expansion in the HD gene']\n",
      "[['Autosomal dominant']]\n",
      "['prolactinoma']\n",
      "[['lipid storage and lipid mobilization']]\n",
      "[['Recent research has revealed that circRNAs can function as microRNA (miRNA) sponges, regulators of splicing and transcription, and modifiers of parental gene expression.']]\n",
      "[['FANCD2 monoubiquitination']]\n",
      "[['The beet Y locus encodes an anthocyanin MYB-like protein that activates the betalain red pigment pathway.']]\n",
      "['transcriptional initiation']\n",
      "['PABP4  binds mRNA poly(A) tails.']\n",
      "['10 nanometers', '10 nm']\n",
      "['component of the central and peripheral circadian clocks for generation of circadian rhythms in mice']\n",
      "[['Nestin']]\n",
      "['DNMT1', 'MET1']\n",
      "['50% to 80%']\n",
      "[['neuroendocrine cells']]\n",
      "[['EGFR', 'epidermal growth factor receptor']]\n",
      "[['Ataxin-3']]\n",
      "['0.7–7/100000 inhabitants']\n",
      "[['mammalian target of rapamycin']]\n",
      "[['T-type calcium channels']]\n",
      "[['55 S']]\n",
      "[['calcitonin gene-related peptide']]\n",
      "[['reciprocal translocation t(11;22) (q24;q12)']]\n",
      "[['HilbertVis']]\n",
      "[['lectin complement pathway']]\n",
      "[['programmed cell death 1']]\n",
      "['autosomal dominant']\n",
      "['blunt thoracic impact causing sudden death']\n",
      "[['Pthirus pubis']]\n",
      "[['The Plakoglobin gene', 'plakoglobin[jup]']]\n",
      "[['focal cortical dysplasia']]\n",
      "[['Charcot-Marie-Tooth (CMT) 4D disease']]\n",
      "['LAMP2A', 'Lysosome-associated membrane protein 2 isoform A']\n",
      "['autosomal dominant mode of inheritance']\n",
      "['The proposed mechanism for postvaccination narcolepsy is one in which an environmental trigger causes or enhances an antibody-mediated autoimmune response in patients with a preexisting genetic susceptibility.']\n",
      "[['The comprehensive characterization of the mouse transcriptome.']]\n",
      "[['Intraflagellar transport (IFT) motor protein DYNC2H1']]\n",
      "[['Reduction of contamination by endogenous biotinylated carboxylases during purification of biotin tagged nuclear proteins.']]\n",
      "['Xist']\n",
      "[['Prion-like domain']]\n",
      "['antioxidant']\n",
      "[['Facioscapulohumeral dystrophy', 'FSHD']]\n",
      "['Rac1']\n",
      "['The identification and quantification of any protein.']\n",
      "['aging research']\n",
      "[['Lys-ɛ-Gly-Gly (K-ɛ-GG) is the remnant produced by trypsin digestion of proteins having ubiquitinated lysine side chains.']]\n",
      "['Notch3 gene']\n",
      "[['Intermediate filaments']]\n",
      "['Low T3 Syndrome isassociatedwithpoor prognosis in patients with acute myocardial infarction']\n",
      "['Fibroblast Growth Factor Receptor 3 (FGFR3)']\n",
      "[['malaria']]\n",
      "[['Phospholamban', 'PLN', 'plb']]\n",
      "[['ZFHX1B', 'ZEB2', 'SIP-1']]\n",
      "[['MDM two binding protein (MTBP)']]\n",
      "['naloxone']\n",
      "[['Heterodimeric Rag GTPases']]\n",
      "[['X-linked dystonia-parkinsonism']]\n",
      "['quadratic']\n",
      "[['Na(+)/Ca(2+) exchanger', 'NCX']]\n",
      "[['Piebaldism is a rare autosomal dominant disorder of melanocyte development characterized by a congenital white forelock and multiple symmetrical stable hypopigmented or depigmented macules.']]\n",
      "[['SLC49']]\n",
      "[['The orexigenic peptides are sythesized in the hypothalamus.']]\n",
      "[['Incontinentia pigmenti or Bloch-Sulzberger syndrome']]\n",
      "[['gene regulatory blocks (GRBs)']]\n",
      "[['frontonasal dysplasia']]\n",
      "['25']\n",
      "['Src, Cortactin and MT1-MMP play an essential role in the formation and function of invadopodia.']\n",
      "[['chromosome XII', 'chromosome 12']]\n",
      "[['S-phase']]\n",
      "['Rett syndrome']\n",
      "[['Dax1 associates with Esrrb and regulates its function in embryonic stem cells.']]\n",
      "[['tyrosine kinase receptor inhibitor']]\n",
      "['HSP70']\n",
      "[['NSD1 gene']]\n",
      "[['Anorexia Athletica']]\n",
      "['Approximately 200', '200', '~200']\n",
      "['SECIS']\n",
      "[['BRG1']]\n",
      "['Multiple']\n",
      "[['Xa']]\n",
      "[['Control of Mouse Erythropoiesis']]\n",
      "['Ultrasound']\n",
      "[['semagacestat']]\n",
      "[['Hypoxanthine guanine phosphoribosyl transferase (HPRT) gene']]\n",
      "['S-adenosyl-L–methionine', 'SAM', 'AdoMet', 'S-Adenosylmethionine', 'adenosylmethionine', 'S-Adenosyl methionine']\n",
      "['Ret']\n",
      "[['7SL RNA']]\n",
      "['lumbosacral']\n",
      "['intensity-based absolute quantification']\n",
      "[['The sodium channel']]\n",
      "[['atrial fibrilation', 'AF']]\n",
      "['The lacrimal and/or salivary glands']\n",
      "['epidermal growth factor receptor (EGFR) gene']\n",
      "[['METLIN is a metabolite database containing tandem mass spectrometry data for each metabolite.']]\n",
      "[['AAUAAA']]\n",
      "[['The repression of hematopoietic genes in erythroid cells.']]\n",
      "['There is an inverse correlation between inflammatory markers and FT3 circulating levels']\n",
      "[['Blue']]\n",
      "['H3K36me3', 'H3K36 trimethylation']\n",
      "[['interleukin-6']]\n",
      "[['stroke']]\n",
      "[['Both nucleolar and cytoplasmic']]\n",
      "[['Collagen']]\n",
      "[['LPIN2']]\n",
      "[['cell viability - cell death assessment']]\n",
      "[['pulmonary arterial hypertension']]\n",
      "[['The RESID Database of Protein Modifications is a comprehensive collection of annotations and structures for protein modifications and cross-links including pre-, co-, and post-translational modifications']]\n",
      "[['Huntington disease']]\n",
      "['The ubiquitin/proteasome pathway']\n",
      "[['Xp21-p11']]\n",
      "[['dabigatran']]\n",
      "[['The Pfam database is a collection of curated protein families.']]\n",
      "['Reads Per Kilobase per Million mapped reads (RPKM)']\n",
      "['aurora kinase']\n",
      "['MCT8', 'monocarboxylate transporter 8']\n",
      "['JNK']\n",
      "[['1:2000']]\n",
      "[['Thapsigargin is a sarcoplasmic/endoplasmic Ca(2+)-ATPase (SERCA) inhibitor.']]\n",
      "['Her2 status is positive']\n",
      "[['CYP17A1']]\n",
      "[['Microcephalic osteodysplastic primordial dwarfism type I (MOPDI)']]\n",
      "['(G/T)GGGCGG(G/A)(G/A)(C/T)']\n",
      "[['T1 mapping can quantitatively characterize myocardial tissue, i.e. fibrosis and edema.']]\n",
      "['LKB1 plays a physiological role in controlling the Wnt-signaling.']\n",
      "['Altered thyroid profile after cardiosurgery is associated with several events in adults and in children']\n",
      "[['The BCR/ABL gene fusion', 'ABL/BCR fusion']]\n",
      "[['Rotor syndrome']]\n",
      "[['EGFR-mutant non small cell lung carcinoma', 'EGFR-mutant NSCLC']]\n",
      "[[\"Gaucher's disease type 1\"]]\n",
      "[[' nuclear']]\n",
      "[['CAGEr']]\n",
      "['No clear results indicating improved life expectancy in professional athletes']\n",
      "[['peroxisome proliferator-activated receptor-α/γ']]\n",
      "[['Amino Acid-DepeLysosomal Membrane Protein SLC38A9']]\n",
      "[['arachnoid cyst']]\n",
      "['RANKL']\n",
      "[['it supresses cell cytokines and differentiation genes']]\n",
      "[['The mTOR pathway']]\n",
      "[['Caspases are intracellular proteases that propagate programmed cell death, proliferation, and inflammation.']]\n",
      "[['Tead (TEA domain) transcription factors.']]\n",
      "['more than 30']\n",
      "[['stationary phase']]\n",
      "[['p53']]\n",
      "['flumazenil']\n",
      "['epidural blood patch']\n",
      "['0.5  to 3  per 100,000 athletes per year']\n",
      "['below 300-330 msec']\n",
      "[['Biologists agree that the ancestor of mitochondria was an alpha-proteobacterium.']]\n",
      "[['X-linked intellectual disability']]\n",
      "[['Sarcoplasmic reticulum Ca(2+)-ATPase', 'SERCA', 'serca2']]\n",
      "['X- linked recessive']\n",
      "[['Lack of the yeast Rrm3p DNA helicase causes replication defects at multiple sites within ribosomal DNA (rDNA), including at the replication fork barrier (RFB).']]\n",
      "['The ubiquitin proteome is the entire set ubiquitinated proteins and of their respective ubiquitination sites.']\n",
      "[['pupillary dilatation (increase of the pupil size)']]\n",
      "['Autosomal dominant']\n",
      "['Experimental autoimmune encephalomyelitis (EAE)']\n",
      "[['Positive']]\n",
      "[['βTrcp', 'beta-Trcp', 'SCFbeta-Trcp', 'SCFbeta-Trcp (Skp1-Cullin1-F-box protein beta transducin repeat-containing protein)', 'Skp1-Cullin1-HOS-Roc1 (SCF(HOS))']]\n",
      "[['The glutamine-rich prion-related domain (PRD)']]\n",
      "['SET domain']\n",
      "[['medicarpin']]\n",
      "[['Chediak-Higashi syndrome']]\n",
      "[['protein phosphatase inhibitor 1', 'inhibitor 1', 'PPI-1', 'I1']]\n",
      "[['Hsp90']]\n",
      "['HLA B*5701 genotyping']\n",
      "['Increased resistance to malaria, reduces the risk of coronary diseases, beneficial effect in terms of longevity']\n",
      "['L-Dopa']\n",
      "['autosomal dominant']\n",
      "[['Both euchromatin and heterochromatin']]\n",
      "[['Light-harvesting pigment-protein complex of Photosystem II', 'LHCII']]\n",
      "['BRCA1 dysfunction']\n",
      "['Galactocerebrosidase is an enzyme that is deficient in Krabbe disease (also known as globoid-cell leukodystrophy). This leads to accumulation of psychosine (galactosylsphingosine) primarily in oligodendrocytes.']\n",
      "[['Yes, there are at least 12 genes associated with human hair color variation such as: TYR, TYRP1, OCA2, SLC45A2, SLC24A5, MC1R, ASIP and KITLG.']]\n",
      "['multiple myeloma']\n",
      "['0.01% -0.1%']\n",
      "[['Calsequestrin', 'casq']]\n",
      "[['Autosomal recessive, except for FANCB, which is X-linked.']]\n",
      "['memory loss']\n",
      "[['CD38']]\n",
      "['missense substitution, Met1Val (M1V), in the DCX gene.']\n",
      "['In HNPCC, the mismatch DNA repair system is involved.']\n",
      "[['OikoBase']]\n",
      "['insulin']\n",
      "[['dermatitis herpetiformis']]\n",
      "['Transcription activator-like effector nucleases (TALEN)', 'Zinc-finger nucleases']\n",
      "['Ixodes ricinus']\n",
      "['3mm']\n",
      "[['The excision of introns from nascent eukaryotic transcripts is catalyzed by the spliceosome.']]\n",
      "[['increase of the osteogenic potential of hDPCs']]\n",
      "[['30x-60x']]\n",
      "['Cervical precancer and similar neoplasias were reduced by 84-100%']\n",
      "['In patients with hypertrophic cardiomyopathy delayed enhancement is associated with heart failure symptoms and left ventricular systolic dysfunction and arrhythmic risk']\n",
      "['major depression']\n",
      "['Global hypomethylation is coupled with focal hypermethylation at CpG islands']\n",
      "[['antiparallel']]\n",
      "['SMIM1']\n",
      "['2.3 megadalton']\n",
      "[['epidermal growth factor receptor']]\n",
      "[['LQVVR']]\n",
      "['Oligonucleotides containing CG and TA dinucleoides']\n",
      "['Artificial urethral sphincter', 'AUS']\n",
      "[['CHEK2 1100delC mutation']]\n",
      "['Thyroid']\n",
      "[['nucleus']]\n",
      "[['CD38']]\n",
      "['Plasmodium species', 'Plasmodium spp.']\n",
      "[['Cardiotoxicity', 'Cardiac toxicity']]\n",
      "[['A-to-I']]\n",
      "[[\"Crohn's disease has a bimodal age distribution of disease onset diagnosis. The peaks (20 and 50 years) may represent different phenotypes or different genetic and/or environmental influences between younger- and older-onset individuals.\"]]\n",
      "[['Celiac disease', 'gluten-associated enteropathy', 'CELIAC SPRU', 'Non tropical spru', 'Gluten Sensitive Enteropath']]\n",
      "[['interleukin-17A']]\n",
      "[['Calcineurin', 'CaN', 'phosphatase 2b']]\n",
      "['H3K36me3']\n",
      "[['Better understand the transcriptional network that regulates macrophage differentiation']]\n",
      "['CYP2C19 genotyping']\n",
      "[['skipping of dystrophin exon 51']]\n",
      "['Pregabalin']\n",
      "[['Hypertension']]\n",
      "[['base excision repair (BER) pathway']]\n",
      "['Ibrutinib']\n",
      "[['Hepcidin contains eight cysteine residues that form four disulfide bridges']]\n",
      "[['5-HT2A']]\n",
      "[['To the outer mitochondrial membrane.']]\n",
      "['Temperature regulation']\n",
      "[['cyclophilin']]\n",
      "[['HEXA']]\n",
      "['mitochondrial inner membrane']\n",
      "['LIberation therapy']\n",
      "[['thyroid']]\n",
      "['autosomal recessive']\n",
      "[['inhibits']]\n",
      "[['30,000-50,000']]\n",
      "['Han Chinese and other Asian populations, except Japanese']\n",
      "['Histone 3 at Thr3']\n",
      "[['non-synonymous']]\n",
      "['p16INK4']\n",
      "[['Frataxin']]\n",
      "['Development']\n",
      "[['mRNA stability']]\n",
      "['H3K4']\n",
      "[['Motor neurons']]\n",
      "[['Amyotrophic lateral sclerosis (ALS)']]\n",
      "[['rolling cycle']]\n",
      "['XK']\n",
      "['mTOR']\n",
      "[[\"Alzheimer's disease\"]]\n",
      "['autosomal dominant']\n",
      "['15']\n",
      "[['In imprinted and repressed, highly compacted loci that are prone to recombination events.']]\n",
      "[['GKT136901']]\n",
      "[['IL-1β']]\n",
      "[['Groucho (Gro) is a Drosophila melanogaster transcriptional corepressor']]\n",
      "[['telomerase']]\n",
      "['Etanercept']\n",
      "[['it is the mouse homolog to the left Alu monomer']]\n",
      "['1/100000']\n"
     ]
    }
   ],
   "source": [
    "for sample in data['questions']:\n",
    "    if sample['type'] == 'factoid':\n",
    "        print (sample['exact_answer'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['epidermal growth factor'], ['betacellulin'], ['epiregulin'], ['heparin-binding epidermal growth factor'], ['transforming growth factor-α'], ['amphiregulin'], ['epigen']]\n",
      "[['let-7a'], ['let-7b'], ['let-7i'], ['miR-21'], ['miR-26a'], ['miR-92'], ['miR-93'], ['miR-100'], ['miR-132'], ['miR-141'], ['miR-145'], ['miR-148a'], ['miR-152'], ['miR-182'], ['miR-200a'], ['miR-200b'], ['miR-200c'], ['miR-203'], ['miR-509-5p'], ['miR-510']]\n",
      "[['neostigmine'], ['pyridostigmine']]\n",
      "[['DVL-1'], ['DVL-2'], ['DVL-3']]\n",
      "[['Class I: sodium channel blockers'], ['ClassII: beta blockers'], ['Class III: potassium channel blockers'], ['Class IV: calcium channel blockers']]\n",
      "[['Notch-1'], ['Notch-2'], ['Notch-3'], ['Notch-4']]\n",
      "[['altered morphology'], ['arrested cell-cycle progression'], ['development of aberrant gene expression with proinflammatory behavior'], ['telomere shortening']]\n",
      "[['OCT4', 'Oct3/4', 'Pou5f1'], ['SOX2'], ['MYC', 'c-MYC'], ['KLF4']]\n",
      "[['childhood Myocerebrohepatopathy Spectrum disorders (MCHS)'], ['Alpers syndrome'], ['Ataxia Neuropathy Spectrum (ANS) disorders'], ['Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA)'], ['autosomal recessive Progressive External Ophthalmoplegia (arPEO)'], ['autosomal dominant Progressive External Ophthalmoplegia (adPEO)']]\n",
      "[['Ryanodine receptor', 'RyR'], ['Calsequestrin', 'CASQ', 'CSQ'], ['Triadin', 'TrD', 'TRN'], ['Junctin', 'JCN', 'JnC', 'JUN']]\n",
      "[['Reflux esophagitis'], ['Achalasia'], ['chronic gastritis'], ['chronic duodenitis'], ['inflammation of the small bowel and colorectum'], ['Ileo-colonic lymphoid nodular hyperplasia (LNH)']]\n",
      "[['epilepsy', 'refractory epilepsy', 'refractory partial-onset seizures'], ['analgesic'], ['CNS disorders']]\n",
      "[['anaemia'], ['thrombocytopenia'], ['renal failure']]\n",
      "[['inhibition of cell migration of human colon carcinoma cells (HCCCs) in wound-healing assays'], ['decreased RhoA activation'], ['inhibition of TGFβ-mediated activation of ERK and JNK'], ['phosphorylation of c-Jun'], ['transactivation of the c-Jun promoter'], ['decreased key TGFbeta responses']]\n",
      "[['Nanog'], ['Pou5f1'], ['SoxB1']]\n",
      "[['G-rich elements'], ['CpG islands'], ['(CTG)n, (CAG)n, (CGG)n, (CCG)n and (GAA)n']]\n",
      "[['L29Q'], ['A8V'], ['A31S'], ['E134D'], ['c.363dupG'], ['A23Q'], ['D145E'], ['C84Y']]\n",
      "[['H3S10p'], ['H3K36me3'], ['H4K20me3'], ['H3K9me3'], ['H3K79me3'], ['H3K9me2'], ['H3K27me1'], ['H3K27me2'], ['H3K27me3']]\n",
      "[['interleukin-4'], ['interleukin-13']]\n",
      "[['FGFR3'], ['FGFR2'], ['FGFR1'], ['MSX2'], ['NELL1'], ['RUNX2'], ['RECQL4'], ['TWIST'], ['SOX6'], ['GNAS']]\n",
      "[['urinary tract infections'], ['genital infections'], ['low blood pressure']]\n",
      "[['Physical activity', 'PA', 'PAL'], ['Constant Strain Postures', 'CSP', 'constant postures'], ['Standing time', 'ST'], ['Lying time', 'LT']]\n",
      "[['JASPAR'], ['JASPAR CORE'], ['JASPAR FAM'], ['JASPAR phyloFACTS'], ['JASPAR 2008 update'], ['JASPAR 2010'], ['JASPAR 2014']]\n",
      "[['follicular ichthyosis'], ['atrichia'], ['photophobia']]\n",
      "[['colchicine'], ['fosfomycin'], ['bacitracin'], ['vancomycin'], ['D-cycloserine', 'seromycin'], ['ampicillin'], ['cinnamycin'], ['ramoplanin'], ['muraymycin'], ['mersacidin']]\n",
      "[['ichthyosis'], ['trichothiodystrophy']]\n",
      "[['Macrophages'], ['T-cells'], ['Fibroblast-like synoviocytes (FLS)'], ['Dendritic cells'], ['synovial fibroblasts']]\n",
      "[['Antithyroid drugs'], ['Corticosteroids'], ['Lithium'], ['Radioiodine']]\n",
      "[['BCL11B'], ['NRoB1'], ['GSTM4'], ['NKX2.2'], ['p53']]\n",
      "[['Brooke-Spiegler syndrome', 'BSS'], ['Cylindromatosis'], ['Multiple Familial Trichoepithelioma', 'MFT']]\n",
      "[['weight gain'], ['growth retardation'], ['hirsutism'], ['obesity'], ['striae'], ['acne'], ['hypertension']]\n",
      "[['PMP22'], ['MPZ'], ['SH3TC2']]\n",
      "[['Enterovirus'], ['Adenovirus'], ['Coxsackie B virus']]\n",
      "[['CCM1/KRIT1'], ['CCM2/OSM/Malcavernin'], ['CCM3/PDCD10']]\n",
      "[['hypomyelination'], ['hypodontia'], ['hypogonadotropic hypogonadism']]\n",
      "[['MET'], ['CMT'], ['DRM']]\n",
      "[['HP1 alpha'], ['CHD proteins', 'Chromodomain helicase DNA-binding protein'], ['CReMM'], ['cmt3'], ['chromointegrases'], ['Polycomb group (PcG) proteins'], ['Cbx2'], ['TgMYST-A'], ['MRG15'], ['MSL3'], ['Swi6'], ['Chp1'], ['dMi-2'], ['Corto'], ['ScoHET1'], ['cpSRP43'], ['CDY', 'chromodomain Y chromosome'], ['transposable elements'], ['like heterochromatin protein', 'LHP1'], ['ADP/ATP translocase 1'], ['CDYL', 'CDY-like protein'], ['CHD1L', 'CHD1-like'], ['NlMof'], ['TIP60'], ['Kismet'], ['Chriz'], ['PICKLE', 'PKL'], ['HP1 beta'], ['HP1 gamma'], ['TgMYST –B'], ['Cbx4'], ['Cbx6'], ['Cbx7'], ['Cbx8'], ['ScoHET2'], ['Cbx3'], ['MPP8'], ['MRG1']]\n",
      "['No drug therapy available today']\n",
      "[['Dopaminergig drugs'], ['Catuama'], ['Capsaicina'], ['Alpha-lipoic acid'], ['Clonazepam'], ['Placebo therapy']]\n",
      "[['c.40_42delAGA(p.Arg14del)', 'PLN R14 del'], ['PLN L39stop', 'PLN R39X'], ['Arg(9) to Cys', 'R9C'], ['Arg(9) to Leu', 'R9L'], ['Arg(9) to His', 'R9H']]\n",
      "[['Resveratrol'], ['Quercetin'], ['Vitamin C'], ['Biostimine'], ['Astaxanthin'], ['Melatonin'], ['coenzyme Q(10)'], ['Creatine'], ['Isoquercetin'], ['Epigallocatechin gallate'], ['n-3 fatty acids'], ['L. rhamnosus IMC 501'], ['L. paracasei IMC 502'], ['docosahexanoic acid (DHA)'], ['eicosapentanoic acid (EPA)'], ['Rhodiola Rosea'], ['Vitamin E'], ['Zinc'], ['whey and/or soy proteins']]\n",
      "[['LC3-II', 'microtubule-associated protein 1 light chain 3'], ['BECN1', 'beclin 1'], ['SQSTM1', 'p62', 'Sequestosome 1']]\n",
      "[['myelodysplastic syndrome (MDS)'], ['Acquired aplastic anemia (AA)'], ['Weaver syndrome'], ['non-Hodgkin lymphoma (NHL)'], ['myeloid leukaemia']]\n",
      "[['ExTopoDB'], ['TMPDB']]\n",
      "[['providing complex regulation'], ['facilitating matching genes and regulatory elements'], ['efficient trancription']]\n",
      "[['defence against retroviral infection'], ['immunity'], ['vesicular trafficking'], ['neural differentiation'], ['embryonic development']]\n",
      "[['PSPC1'], ['SFPQ']]\n",
      "[['GAC'], ['SHMT2'], ['AMPAR'], ['Orai1'], ['Orai3']]\n",
      "[['PLN L39X nonsense mutation'], ['PLN Leu39Ter'], ['PLN -42 C>G'], ['PLN -77A-->G']]\n",
      "[['3'], ['6'], ['8'], ['12'], ['15'], ['17'], ['21'], ['X'], ['Y']]\n",
      "[['fluorouracil'], ['epirubicin'], ['cyclophosphamide']]\n",
      "[['D22S1'], ['D22S15']]\n",
      "[['motif conservation'], ['fuzzy itemset mining'], ['combinatorial methods']]\n",
      "[['neurodegenerative disease'], ['epilepsy'], ['schizophrenia'], [\"Huntington's disease (HD)\"], [\"Alzheimer's disease (AD)\"], ['neuroinflammation'], ['osteosarcoma'], ['chronic lymphocytic leukemia (CLL)'], ['angiogenesis'], ['eye disease'], ['alcoholic liver disease'], ['progressive supranuclear palsy (PSP taupathy)'], ['mild cognitive impairment']]\n",
      "[['EAAC1', 'EAAT3'], ['GLT-1', 'glutamate transporter-1', 'excitatory amino acid transporter 1'], ['GLAST', 'Glutamate/aspartate transporter'], ['GluR4', 'AMPA receptor glutamate receptor 4'], ['VGLUT1', 'vesicular glutamate transporter']]\n",
      "[['fluorochromes', 'fluorescence'], ['Sypro Ruby'], ['Colloidal Coomassie Blue'], ['Coomassie Blue'], ['Silver staining'], ['Coomassie Brilliant Blue']]\n",
      "[['sagittal'], ['lambdoid']]\n",
      "[['Hedgehog'], ['Notch'], ['Wnt'], ['c-Met'], ['erbB2'], ['IGF-R'], ['TrkC'], ['Myc']]\n",
      "[['fever'], ['enathema'], ['skin rash'], ['nausea'], ['vomiting'], ['diarrhea'], ['cough'], ['gastrointestinal disorders'], ['anaphylactic shock'], ['respiratory symptoms']]\n",
      "[['CD44'], ['PARP1'], ['Mage-A4'], ['LSR'], ['RAB25'], ['S100A14'], ['MUC1'], ['Hsp90'], ['Actin'], ['14-3-3'], ['vimentin'], ['HSP70'], ['CK18'], ['moesin'], ['IDH2'], ['CRABP2'], ['SEC14L2'], ['beta-catenin'], ['MUC18'], ['Stat1'], ['CD74']]\n",
      "[['flaccid dysarthria'], ['spastic dysarthria'], ['ataxic dysarthria'], ['hyperkinetic dysarthria'], ['hypokinetic dysarthria'], ['mixed dysarthria']]\n",
      "[['H3K27me3'], ['H3K27Ac'], ['H3K9me3'], ['H3K36me']]\n",
      "[['pSer-Xaa-Xaa-Ser'], ['K/R-X-K/R-X-X-S/T'], ['SLS and acidic cluster motifs'], ['SerP/ThrP-Xaa-Xaa-Ser/Thr']]\n",
      "[['rivaroxaban'], ['warfarin']]\n",
      "[['perilipins'], ['adipose differentiation-related protein', 'ADFP'], ['LSDP5', 'lipid storage droplet protein 5'], ['tail-interacting protein of 47 kilodaltons', 'TIP47'], ['S3-12']]\n",
      "[['iron-restricted anemias'], ['anemia of inflammation'], ['anemia of cancer'], ['anemia of chronic kidney disease'], ['anemia of chronic disease']]\n",
      "[['eye responses'], ['motor responses'], ['brainstem reflexes'], ['respiration']]\n",
      "[['nose'], ['ear'], ['meniscus']]\n",
      "[['congenital cataracts'], ['facial dysmorphism'], ['peripheral neuropathy']]\n",
      "[['Ras'], ['c-Abl'], ['Raf'], ['Myc'], ['Skp2'], ['BRAF'], ['AKT'], ['HDAC2'], ['p38 MAPK'], ['Caveolin-1'], ['Mek1']]\n",
      "[['Aspartyl-beta-hydroxylase', 'Aspartyl (asparaginyl)-beta-hydroxylase', 'AbetaH', 'AAH', 'BAH'], ['humbug'], ['junctate'], ['junctin'], ['junctin isoform']]\n",
      "[['cell proliferation'], ['organ size control'], ['cancer development'], ['tissue homeostasis'], ['cell differentiation']]\n",
      "[['genomics'], ['transcriptomics'], ['proteomics'], ['metabolomics'], ['degradomics'], ['fluxomics'], ['epigenomics'], ['glucomics']]\n",
      "[['alpha-tropomyosin', 'TPM1'], ['β-myosin heavy chain', 'MYH7'], ['troponin T', 'TNNT2'], ['Desmoplakin', 'DSP'], ['mindbomb homolog 1', 'MIB1']]\n",
      "[['antiinflammatory steroid and non steroid drugs'], ['inotropic agents'], ['mechanical support']]\n",
      "[['PARK2'], ['PARK7', 'DJ-1'], ['PINK1'], ['PARK9', 'ATP13A2'], ['PARK14', 'PLA2G6'], ['PARK15', 'FBX07']]\n",
      "[['CPVT', 'catecholaminergic polymorphic ventricular tachycardia'], ['HCM', 'hypertrophic cardiomyopathy']]\n",
      "[['hydrocephalus'], ['cerebral calcification'], ['chorioretinitis']]\n",
      "[['cell proliferation'], ['pluripotency'], ['cell fate determination'], ['G1 to S transition'], ['germ cell migration'], ['tumour development']]\n",
      "[['R403Q', 'Arg403Gln'], ['Q1065H'], ['Arg-249-->Gln']]\n",
      "[['aortic root dilation'], ['mitral valve prolapse'], ['aortic regurgitation'], ['mitral valve regurgitation']]\n",
      "[['growth rate deficit in both roots and shoots'], ['lowered activity of specific mitochondrial enzymes associated with respiratory metabolism'], ['impaired seedling establishment']]\n",
      "[['H-Ras'], ['N-Ras'], ['K-Ras4A'], ['K-Ras4B']]\n",
      "[['Alemtuzumab'], ['Campath-1H']]\n",
      "[['subgenual cingulate gyrus'], ['anterior limb of the capsula interna'], ['nucleus accumbens'], ['medial forebrain bundle'], ['habenula'], ['ventral caudate nucleus']]\n",
      "[['ponezumab'], ['solanezumab'], ['bapineuzumab'], ['Gantenerumab']]\n",
      "[['rs7140952 polymorphism of DIO2'], ['Ala92 type 2 deiodinase allele']]\n",
      "[['Snail1 (Snail)'], ['Snail2 (Slug)'], ['Zeb1'], ['Twist'], ['SIP1'], ['DeltaEF1']]\n",
      "[['Prader Willi Syndrome'], ['Angelman syndrome'], ['Beckwith-Wiedemann syndrome'], ['Hydatidiform mole'], ['Cancer'], ['Silver-Russell syndrome'], ['Diabetes']]\n",
      "[['loss of memory'], ['dysmnesia']]\n",
      "[['medullary thyroid carcinoma'], ['gastroenteropancreatic tumors'], ['pheochromocytoma'], ['paraganglioma']]\n",
      "[['deoxycoformycin'], ['pentostatin'], ['nelarabine']]\n",
      "[['no associations found yet']]\n",
      "[['depression during childhood and adolescence'], ['Premature ejaculation', 'PE'], ['erectile dysfunction'], ['Insomnia'], ['postprostatectomy established stress urinary incontinence', 'SUI'], ['mood and anxiety disorders during pregnancy and breast feeding'], ['hot flashes', 'postmenopausal symptoms'], ['bulimia'], ['benzodiazepine/alcohol dependence'], ['fibromyalgia'], ['behavioral disorders in dementia'], ['schizophrenia'], ['chronic pain disease'], ['diabetic neuropathy']]\n",
      "['αvβ3 integrin', 'ανβ5 integrin', ['αvβ5', 'αvβ3']]\n",
      "[['TP53'], ['ATM'], ['NOTCH1'], ['XPO1'], ['MYD88'], ['KLHL6'], ['SF3B1'], ['ZMYM3'], ['MAPK1'], ['FBXW7'], ['DDX3X']]\n",
      "[['1'], ['3'], ['5'], ['6'], ['8'], ['9'], ['12'], ['13'], ['15'], ['16'], ['18'], ['22'], ['X'], ['Y']]\n",
      "[['benign ovarian tumor'], ['ascites'], ['pleural effusion']]\n",
      "[['Blood Tests'], ['Imaging Tests'], ['Kidney Biopsy'], ['Urine Tests'], ['estimated GFR (eGFR)'], ['Decreased tryptophan (TRP)']]\n",
      "[['Itramniotic bleeding'], ['CMV infection'], ['Cystic Fibrosis (CF)'], ['Fetal aneuploidy']]\n",
      "[['isoform characteriztion'], ['determination of the type and location of post translational modifications']]\n",
      "[['trypsin'], ['Asp-N'], ['chymotrypsin'], ['LysC'], ['Glu-C'], ['thermolysin']]\n",
      "[['Mfd'], ['NusA']]\n",
      "[['KCNQ1', 'KVLQT1', 'KCNA9'], ['KCNE1'], ['KCNE2'], ['KCNH2', 'HERG'], ['SCN5A'], ['CAV3'], ['SCN4B'], ['AKAP9'], ['SNTA1'], ['KCNJ5'], ['Ankyrin-B gene']]\n",
      "[['skin hyperextensibility'], ['dystrophic scarring'], ['joint hypermobility']]\n",
      "[['Oxcarbazepine'], ['Opioids alone, in rotations or with Analgesics (e.g. Ketamine and Lidocaine infusion)'], ['Opioids and Benzodiazepines - for terminal care'], ['Pregabalin'], ['Tricyclic Antidepressants'], ['Lidocaine 5% patches for chronic localized neuropathic pain'], ['Ketamine']]\n",
      "[['Type 2 deiodinase'], ['Tipe 3 deiodinase']]\n",
      "[['CYP2C9'], ['VKORC1'], ['ORM1'], ['CYP4F2'], ['EPHX1'], ['CYP2C18'], ['CYP2C19'], ['CYP3A5'], ['protein S'], ['clotting factor V'], ['PROC'], ['GGCX']]\n",
      "[['Dapagliflozin'], ['Empagliflozin'], ['Canagliflozin']]\n",
      "[['schizophrenia', 'schizophrenia psychosis'], ['schizoaffective disorder'], ['delusional disorder'], ['psychotic relapse in neuroleptic malignant syndrome'], ['attention deficit hyperactivity disorder (ADHD) with negativism or conduct disorders'], ['psychotic disorders']]\n",
      "[['abnormal QT-U complex'], ['ventricular arrhythmia'], ['periodic paralysis'], ['facial dysmorphisms'], ['skeletal dysmorphisms']]\n",
      "[['SPINK5 gene'], ['LEKTI protein']]\n",
      "[['Notch intracellular domain (NICD)', 'NICD', 'Intracellular part of Notch', 'ICN', 'NIC'], ['Transcription factor CSL', 'RBP-Jkappa', 'CBF1', 'Suppressor of Hairless', 'Lag-1'], ['The coactivator protein Mastermind-like 1', 'MAML-1']]\n",
      "[['Ligand-based, pharmacophore modeling'], ['Structure-base, pharmacophore modeling']]\n",
      "[['RNA polymerase II'], [\"RNA guanylyltransferase and 5'-phosphatase\"], ['RNA guanine-7 methyltransferase']]\n",
      "[['BIX-01294'], ['TM2-115'], ['2,4-pyridinedicarboxylic acid', '2,4-PDCA'], ['3-deazaneplanocin A', 'DZNep'], ['Trichostatin A', 'TSA'], ['Psammaplin A', 'PsA'], ['Sulforaphane', 'SFN']]\n",
      "[['COX-2'], ['ANF'], ['estrogen receptor (ER)alpha gene'], ['calsequestrin gene', 'casq2'], ['cTnT'], ['MCK'], ['alpha-cardiac actin'], ['sarco(endo)plasmic reticulum Ca2+-ATPase', 'SERCA'], ['MLC-2'], ['alpha-cardiac myosin heavy chain gene'], ['phosphoglycerate mutase', 'PGAM-M'], ['cardiac troponin C', 'cTnC']]\n",
      "[['TALEN'], ['Crispr/CAS'], ['zinc-finger nucleases']]\n",
      "[['caspase-1'], ['caspase-4'], ['caspase-5']]\n",
      "[['tunicates'], ['diptera'], ['worm'], ['yeast']]\n",
      "[['everolimus'], ['rapamycin']]\n",
      "[['Ancora'], ['TFCONES']]\n",
      "[['Ablation of ILK in heart results in dilated cardiomyopathy and spontaneous heart failure'], ['Ablation of ILK in fibroblasts leads to impaired healing due to a severe reduction in the number of myofibroblasts'], ['Ablation of ILK in osteoclasts inhibits bone resorption'], ['Ablation of ILK in liver results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration and in abnormal histology'], ['Ablation of ILK in podocytes caused an aberrant distribution of nephrin and alpha-actinin-4']]\n",
      "[['MT1'], ['MT2']]\n",
      "[['DNA-dependent RNA polymerase II'], ['RNA polymerase II'], ['RNAP II']]\n",
      "[['HSP90'], ['CDC37'], ['GRP75'], ['HSP60'], ['LRPPRC'], ['TUFM'], ['PICK1'], ['PSMA7', 'XAPC7'], ['Pael receptor']]\n",
      "[['weight loss'], ['exercise', 'physical activity', 'fitness'], ['dermatology'], ['alcohol-use behavior change'], ['urine flow'], ['fluid intake']]\n",
      "[['DKC1'], ['TERC'], ['TERT'], ['NOP10'], ['NHP2'], ['TIN2'], ['C16orf57'], ['TCAB1']]\n",
      "[['Cufflinks'], ['RSEM'], ['Flux Capacitor'], ['Mitie'], ['Miso'], ['Tigar'], ['Montebello'], ['Drut'], ['Traph'], ['Pome'], ['IsoformEx'], ['Neuma']]\n",
      "[['V60L'], ['D84E'], ['V92M'], ['R151C'], ['R160W'], ['R163Q'], ['D294H']]\n",
      "[['Silver syndrome/spastic paraplegia 17'], ['Distal hereditary motor neuropathy type V'], ['Charcot-Marie-Tooth disease type 2 (CMT2) with predominant hand involvement']]\n",
      "[['SB225002'], ['G31P'], ['SCH-527123'], ['AZ10397767'], ['SCH-479833']]\n",
      "[['catecholaminergic polymorphic ventricular tachycardia (CPVT)'], ['familial hypertrophic cardiomyopathy']]\n",
      "[[\"Parkinson's disease\"], ['COPD', 'Chronic  obstructive pulmonary disease', 'Chronic Obstructive Airways Disease', 'Chronic Obstructive Lung Disease'], ['Food hypersensitivity', 'Allergy'], ['Niacin induced flushing'], ['Hemophilia'], ['Heartburn', 'Reflux', 'GERD', 'Esophageal reflux'], ['Headache', 'Migraine', 'migraine headache', 'Migraine Disorder', 'Migraine Headaches']]\n",
      "[['MAP1LC3A', 'microtubule-associated protein-1 light chain 3A', 'LC3A'], ['MAP1LC3B', 'microtubule-associated protein-1 light chain 3B', 'LC3B'], ['MAP1LC3C', 'microtubule-associated protein-1 light chain 3C', 'LC3C'], ['GABARAP', 'GABA(A) receptor-associated protein', 'Gamma-aminobutyric acid receptor-associated protein', 'MM46'], ['GABARAPL1', 'Gamma-aminobutyric acid receptor-associated protein-like 1', 'Early estrogen-regulated protein', 'GABA(A) receptor-associated protein-like 1', 'Glandular epithelial cell protein 1', 'GEC-1'], ['GABARAPL2', 'Gamma-aminobutyric acid receptor-associated protein-like 2', 'GABA(A) receptor-associated protein-like 2', 'Ganglioside expression factor 2', 'GEF-2', 'General protein transport factor p16', 'Golgi-associated ATPase enhancer of 16 kDa', 'GATE-16', 'MAP1 light chain 3-related protein']]\n",
      "[[\"Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial, European Clinical Trials database\\\\, as EudraCT: 2009-016278-34 and the Clinical Trials Registry\\\\, India as CTRI/2010/091/000250.\"], [\"IMProving Adherence using Combination Therapy (IMPACT)', Australian New Zealand Clinical Trial Registry (ACTRN12606000067572)\"], ['Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP)'], ['Phase II study of the Polycap, double-blind\\\\, randomised trial\\\\, registered with ClinicalTrials.gov\\\\, number NCT00443794', 'ndian Polycap Study, TIPS'], ['Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term-risk (CRUCIAL trial)'], ['GEMINI trial, 14-week\\\\, open-label trial conducted in 1220 patients from the USA'], ['GEMINI-Australia, Asia\\\\, Latin America\\\\, Africa/Middle East (AALA) study'], ['JEWEL 1 conducted among 1138 patients from the UK and Canada'], ['JEWEL 2 conducted in 1107 patients from Europe'], ['CAPABLE54, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points\\\\, in the USA'], ['CUSP (The Caduet® in an Untreated Subject Population trial)'], ['TOGETHER trial'], ['A randomised controlled trial in seven countries – Australia, Brazil\\\\, India\\\\, Netherlands\\\\, New Zealand\\\\, United Kingdom and United States\\\\, Australian New Zealand Clinical Trials Registry (ACTRN 12607000099426)'], ['Second Indian Polycap Study, TIPS-2']]\n",
      "[['YAP'], ['TAZ']]\n",
      "[['myosins-Ibeta'], ['myosin-VI'], ['myosin-VIIa']]\n",
      "[['I-kBs'], ['Sef'], ['NF-kB1 (p105)'], ['NF-kB2 (p100)']]\n",
      "[['non-small cell lung cancer'], ['glioblastoma']]\n",
      "[['Ccl4'], ['neurotensin'], ['vascular endothelial growth factor'], ['metalloproteinases-1'], ['thrombospondin 3'], ['Slit2'], ['hepatocyte growth factor'], ['Wnt2']]\n",
      "[['Cdc45'], ['Mrc1'], ['Tof1-Csm3 complex'], ['FACT'], ['Ctf4']]\n",
      "[['Aip1'], ['Ede1'], ['Inn1']]\n",
      "[['etioplasts (mainly)'], ['chloroplasts (in young developing leaves during the night)']]\n",
      "[['monoclonal antibodies'], ['treatment for refractory asthma'], ['treatment for eosinophilic disease'], ['neutralize interleukin 5'], ['reduce eosinophil counts']]\n",
      "[['GJB1'], ['MPZ'], ['INF2'], ['DNM2'], ['YARS'], ['GNB4'], ['NEFL'], ['MFN2'], ['LRSAM1'], ['GDAP1'], ['PMP22'], ['LITAF'], ['EGR2']]\n",
      "[['NF-kappa B (p50/p65)'], ['ATF-2'], ['c-jun'], ['IRF-3'], ['IRF-7'], ['IRF-1']]\n",
      "[['Neighbourhood Consistent PC (NCPC) algorithms'], ['MMDiff'], ['cosmo'], ['dPattern'], ['TFBS']]\n",
      "[['Mindfulness Based Therapy (MBT)'], ['Multimodal Anxiety and Social Skills Intervention (MASSI) program'], ['modified version of the Coping Cat program', '(cognitive-behavioral therapy; CBT'], ['Family cognitive-behavioral therapy'], ['Individual cognitive-behavioral therapy'], ['Conflict management for couples', 'even when conflict and family distress is low'], ['Sertraline']]\n",
      "[['istradefylline'], ['preladenant']]\n",
      "[['Brain lesions'], ['Kidney lesions'], ['Lung lesions'], ['renal angiomyolipoma'], ['subependymal giant cell astrocytoma (SEGA)'], ['seizures'], ['mental detardation'], ['autism'], ['hepatic lesions'], ['Pulmonary lymphangioleiomyomatosis']]\n",
      "[['anti-freeze protein-3', 'AFP-III'], ['anti-freeze glycoprotein'], ['Thermal hysteresis protein'], ['AFP-I'], ['AFP-II']]\n",
      "[['miRNA'], ['snRNA'], ['snoRNAs'], ['scaRNAs'], ['piRNAS']]\n",
      "[['mTOR'], ['Rictor'], ['mSin1'], ['mLST8/GβL'], ['PRR5']]\n",
      "[['HU'], ['IHF'], ['H-NS']]\n",
      "[['Obesity'], ['High blood pressure', 'Hypertension'], ['High serum triglycerides'], ['Low high-density cholesterol (HDL) levels'], ['Diabetes type 2'], ['Dyslipidaemia']]\n",
      "[['ZD6474'], ['SU11248'], ['AEE 788'], ['sorafenib'], ['vatalanib'], ['AG-013736']]\n",
      "[['Short palindromic sequences (4, 5 and 6 bp palindromes)'], ['Palindromes corresponding to sites for restriction enzymes from other species']]\n",
      "[['KRAS'], ['EGFR'], ['BRAF'], ['T53']]\n",
      "[['miR-155'], ['miR-146a'], ['miR-124a'], ['miR-222'], ['miR-223'], ['miR-203'], ['miR-346'], ['miR-132'], ['miR-363'], ['miR-498'], ['miR-15a'], ['miR-16'], ['miR-18a']]\n",
      "[[\"RNA guanylyltransferase and 5'-phosphatase (RNGTT)\"], ['RNA guanine-7 methyltransferase (RNMT or hMTr1)'], ['RNMT-activating mini-protein (RAM)'], ['RNA polymerase II'], ['S-adenosylhomocysteine hydrolase (SAHH)'], ['Myc']]\n",
      "[['GeneView'], ['PPI finder'], ['PreBIND', 'Textomy'], ['BioMap'], ['eFIP', 'Extracting Functional Impact of Phosphorylation'], ['Protopia'], ['STRING']]\n",
      "[['Cysteine-rich protein 1 (CRP1)'], ['Fascin'], ['Macrophage actin-associated tyrosine phosphorylated protein (MAYP/PSTPIP2)'], ['Insulin receptor tyrosine kinase substrate p53 (IRSp53)'], ['Missing in metastasis protein (MIM)'], ['Eps8'], ['Diaphanous-related formin (dDia2)'], ['Vasodilator-stimulated phosphoprotein (VASP)']]\n",
      "[['androgen replacement trials'], ['omega-3 fatty acid supplementation', 'NCT00794079']]\n",
      "[['Microinjection'], ['electroporation'], ['via viral vectors'], ['liposomes']]\n",
      "[['dementia'], ['gait disturbances'], ['urinary incontinence']]\n",
      "[['cystine disulfide bonds'], ['amide bonds'], ['hydrogen bonds']]\n",
      "[['Sarco-Endoplasmic Reticulum Calcium ATPase 2A', '(SERCA2A)'], ['Inhibitor 1 of Protein Phosphatase 1B', '(I-1)'], ['Protein Phosphatase 1B', '(PP1B)'], ['Yes Associated Protein', '(YAP)'], ['Survivin'], ['S100A1']]\n",
      "[['LRRK2 gene mutation'], ['Human L-Ferritin'], ['The genotypes of five specific single-nucleotide polymorphisms (SNPs) in three genes'], ['Homozygosity for the T-allele of BTBD9 rs9296249'], ['MEIS1'], ['Intragenic guanosine triphosphate cyclohydrolase-1 duplication']]\n",
      "[['quinoline-3-carbonitriles'], ['indazoles'], ['thieno-pyrimidines']]\n",
      "[['nausea'], ['dizziness / lightheadedness'], ['insomnia'], ['fatigue'], ['vomiting'], ['reduced caloric intake / apetite'], ['increased self-rated alertness'], ['decreased tiredness'], ['(horses) some passage of semifluid fecal material'], ['(horses) intermittent penile relaxation'], ['(horses) mild sedation']]\n",
      "[['network-based methods']]\n",
      "[['allophycocyanin (APC)'], ['C-Phycocyanin (C-Pc)'], ['B-Phycoerythrin (B-PE)'], ['R-phycoerythrin (R-PE)']]\n",
      "[['X-linked'], ['autosomal dominant'], ['autosomal recessive']]\n",
      "[['ARB1'], ['ARB2'], ['TAK1'], ['p38'], ['TRalpha1']]\n",
      "[['HMMpTM'], ['MetaTM'], ['Philius'], ['HMM_RA'], ['HMMTOP'], ['MEMSAT3'], ['HMM-TM'], ['TMHMM'], ['Phobius'], ['SignalP']]\n",
      "[['Flybow'], ['Drosophila Brainbow']]\n",
      "[['fibroblast growth factors (FGFs)'], ['TGF-β1'], ['TGF-β2'], ['TNF-α'], ['CCN family'], ['Sonic Hedgehog (SHh)'], ['Notch1'], ['GF-β'], ['Wnt'], ['EGF'], ['bFGF'], ['IGF-I'], ['IGF-II']]\n",
      "[['H3K4me1'], ['H3K27ac']]\n",
      "[['their magnitude of size'], ['transcription factor density'], ['binding of transcriptional machinery'], ['associated with genes driving cell differentiation']]\n",
      "[['negative chronotropy', 'lower heart rate'], ['negative inotropy'], ['resistance to ischemic injury'], ['reduced cardiac output']]\n",
      "[['non-small cell lung'], ['gastric'], ['esophageal'], ['colorectal'], ['primary peritoneal'], ['pancreatic'], ['ovarian'], ['cervical']]\n",
      "[['human kallikrein-related peptidase 3'], ['hK3']]\n",
      "[['askHERMES'], ['EAGLi'], ['HONQA'], ['INDOC']]\n",
      "[['Type 1 deiodinase'], ['Tipe 3 deiodinase']]\n",
      "[['deafness'], ['onychodystrophy'], ['osteodystrophy'], ['mental retardation'], ['seizures']]\n",
      "[['LDL receptor'], ['ChREBP', 'Carbohydrate response element binding protein'], ['ME', 'malic enzyme'], ['cytochrome P450 oxidoreductase']]\n",
      "[['X-linked Charcot-Marie-Tooth disease type 5 (CMTX5)'], ['Arts syndrome'], ['Non-syndromic sensorineural deafness (DFN2)']]\n",
      "[['JAK1'], ['JAK2']]\n",
      "[['aptamers'], ['enzymes'], ['streptavidin'], ['concanavalin A'], ['carboxylic-modified'], ['TiO2'], ['antibodies'], ['SELEX library'], ['synthesized DNA'], ['C18'], ['C8'], ['oligo(dT)']]\n",
      "[['parathyroid gland'], ['pancreas'], ['pituitary gland']]\n",
      "[['Sonic hedgehog', 'SHH'], ['Indian hedgehog', 'IHH'], ['Desert hedgehog', 'DHH']]\n",
      "[['patient health questionnaire-2'], ['patient health questionnaire-9']]\n",
      "[['HU'], ['H-NS'], ['IHF']]\n",
      "[['X-linked spinal and bulbar muscular atrophy (SBMA)'], ['Fragile X syndrome of mental retardation (FRAXA)'], ['Fragile X syndrome of mental retardation (FRAXE)'], [\"Huntington's disease (HD)\"], ['Spinocerebellar ataxia type 1 (SCA1)'], ['Dentatorubral-pallidoluysian atrophy (DRPLA)']]\n",
      "[['BCR-ABL'], ['Platelet-derived growth factor receptor (PDGFR)'], ['c-Kit']]\n",
      "[['epilepsy'], ['subependymal giant cell astrocytomas'], ['lymphangioleiomyomatosis'], ['rhabdomyoma'], ['renal angiomyolipomas'], ['cortical tubers'], ['neurofibromas'], ['angiofibromas'], ['mental retardation'], ['behavioral disorders']]\n",
      "[['dexamethasone'], ['cytarabine'], ['cisplatin'], ['rituximab']]\n",
      "[['proximal limb muscle weakness'], ['fatigability'], ['decreased deep-tendon reflexes'], ['autonomic symptoms'], ['small-cell lung cancer']]\n",
      "[['A. actinomycetemcomitans'], ['P. gingivalis'], ['T. denticola'], ['T. forsythia'], ['P. intermedia'], ['F. nucleatum']]\n",
      "[['POP2'], ['CAF1Z'], ['PARN'], ['PAN2'], ['CCR4'], ['Nocturnin'], ['ANGEL'], [\"2'-PDE\"]]\n",
      "[['IRanges'], ['GenomicRanges'], ['GenomicFeatures']]\n",
      "[['enriched for phosphorylated peptides using titanium dioxide'], ['sequential elution from IMAC'], ['simple derivatization procedure based on phosphoramidate chemistry'], ['antiphosphotyrosine antibodies']]\n",
      "[['H3K36me3']]\n",
      "[['schizophrenia'], ['major depressive disorder']]\n",
      "[['Multiple Sclerosis'], ['Alzheimer disease'], ['Rheumatoid Arthritis', 'RA'], ['Prion Diseases'], ['Cancer']]\n",
      "[['CLOCK'], ['BMAL1'], ['Per'], ['Cry'], ['CKlε']]\n",
      "[['Barrow Ruptured Aneurysm Trial (BRAT)'], ['international subarachnoid aneurysmal trial (BRAT)'], ['FIAT study']]\n",
      "[['Pittsburgh compound B'], ['Florbetaben (BAY 94-9172)'], ['Florbetapir F 18 (18F-AV-45)'], ['18F flutemetamol (flute)']]\n",
      "[['H2'], ['H3']]\n",
      "[['Codon 12'], ['Codon 13'], ['Codon 61'], ['Codon 146'], ['Codon 18'], ['Codon 31'], ['Codon 15']]\n",
      "[['Any patient with adrenocortical cancer (ACC), irrespective of age and family history.'], ['All families with a p53 mutation must have at least one family member with a sarcoma, breast, brain, or adrenocortical carcinoma (ACC).']]\n",
      "[['crizotinib-resistant ALK-positive metastatic NSCLC patients'], ['crizotinib-naïve ALK-positive metastatic NSCLC patients']]\n",
      "[['TRIAC', 'TETRAC']]\n",
      "[['situs inversus'], ['bronchiectasis'], ['sinusitis']]\n",
      "[['host-mediated defense against exogenous viruses'], ['defense against endogenous transposable elements']]\n",
      "[['H3K9Me1', 'H3K9Me2', 'H3K9me3'], ['H3K27me1'], ['H3K27me2'], ['H4K20me3'], ['H3K79me3'], ['H3S10']]\n",
      "[['tolcapone'], ['entacapone']]\n",
      "[['ryanodine receptor 2', 'RYR2'], ['calsequestrin 2', 'CASQ2'], ['triadin', 'TRDN'], ['calmodulin 1', 'CALM1'], ['potassium channel, inwardly rectifying subfamily J, member 2', 'KCNJ2']]\n",
      "[['LigandScout program'], ['Discovery Studio program', '3D QSAR Pharmacophore Generation module'], ['Catalyst', 'HipHop module', 'HypoGen module'], ['PharmaGist'], ['Genetic Algorithm Similarity Program (GASP)'], ['Molecular Operating Environment (MOE)', 'Pharmacophore Elucidation']]\n",
      "[['Leigh syndrome'], [\"Leber's hereditary optic neuropathy and/or dystonia\"]]\n",
      "[['nanoplasmonics', 'biosensors'], ['liquid biopsy'], ['Cancer personalized profiling by deep sequencing', 'CAPP-Seq'], ['electrochemical sensors']]\n",
      "[['Type 2 deiodinase'], ['Type 3 deiodinase']]\n",
      "[['BBF', 'beta-barrel finder'], ['BETAWARE'], ['BOCTOPUS'], ['BOMP'], ['BTMX', 'Beta barrel TransMembrane eXposure'], ['HHomp'], ['HMM-B2TMR'], ['OMBBpred'], ['PROFtmb'], ['PRED-TMBB'], ['TMB-Hunt'], ['TBBPred'], ['TMBETAPRED-RBF'], ['TMBHMM'], ['TransFold'], ['TMBpro'], ['TMBKNN'], ['Wimley'], ['TMBETA-NET']]\n",
      "[['mouse lethality assay'], ['by mass spectrometry'], ['bioassay'], ['differentiated cell models'], ['peptide cleavage assay'], ['FDC (functional dual coating) microtitre plate immuno-biochemical assay'], ['endopeptidase activity monitored via UV-Visible spectroscopy']]\n",
      "[['peripheral heterochromatin'], ['perinucleolar heterochromatin'], ['pericentromeric heterochromatin']]\n",
      "[['UvrA'], ['UvrB'], ['UvrC nuclease'], ['UvrD 1A helicase'], ['DNA polymerase I'], ['Ligase'], ['Cho nuclease (instead of UvrC)'], ['PcrA helicase (instead of Uvrd, in gram-positive bacteria)']]\n",
      "[['genes which are involved in metabolism, transport, and signaling processes'], ['gene conversion-prone regions']]\n",
      "[['prostate cancer'], ['gastric tumor'], ['melanoma'], ['premyelocytic leukemia']]\n",
      "[['GFI1B'], ['NBEAL2']]\n",
      "[['Gfi-1b'], ['MeCP1'], ['ACF/WCRF complex'], ['FOG-1'], ['TAL-1'], ['Ldb1'], ['LMO2-C'], ['PIAS3'], ['RUNX1'], ['Ski'], ['EKLF'], ['SP1'], ['CBP/p300'], ['PU.1']]\n",
      "[['H2A.X'], ['H2A.Z'], ['H1R']]\n",
      "[['Sleep monitoring'], ['Body weight'], ['Blood pressure control'], ['Heart failure control'], ['vital signs'], ['fetal heart signal'], ['uterine contractions'], ['Electrocardiograms', 'ECG'], ['Temperature'], ['Oxygen saturation', 'SaO2'], ['breath rate'], ['Step-counting'], ['Falls detector']]\n",
      "[['lung cancer'], ['pulmonary embolism'], ['respiratory distress syndrome'], ['methanol intoxication'], ['kidney diseases'], ['liver diseases'], ['Helicobacter pylori infection'], ['asthma'], ['sepsis'], ['heart failure'], ['diabetes'], ['tuberculosis']]\n",
      "['ischemic stroke', 'central venous catheter (CVC) occlusions', 'thrombolysis', 'myocardial infarction', 'acute pulmonary embolism', 'deep vein thrombosis', 'limb artery occlusions', ['Ischaemic Stroke'], ['Acute Myocardial Infarction', 'AMI', 'MI'], ['Pulmonary Thromboembolism'], ['Vein Thrombosis'], ['Arterial Thrombotic Occlusion']]\n",
      "[['Human disc-large homolog', 'hDlg'], ['caveolin-1'], ['IQ motif-containing GTPase-activating protein 1', 'IQGAP1'], ['kinase suppressor of Ras', 'KSR'], ['MEK partner-1', 'MP-1'], ['beta-arrestin'], ['Sef'], ['14-3-3'], ['mitogen-activated protein kinase organizer 1']]\n",
      "[['DNMT1'], ['DNMT2'], ['DNMT3']]\n",
      "[['retrotransposons containing LTRs (Long Terminal Repeats)'], ['retrostransposons lacking LTRs (Long Terminal Repeats)']]\n",
      "[['Gfi-1b'], ['MeCP1 complex'], ['ACF/WCRF complex'], ['fog-1'], ['tal-1']]\n",
      "[['myotonic dystrophy type 2'], ['Friedreich ataxia'], ['spinocerebellar ataxia type 10'], ['autosomal dominant optic atrophy'], ['Menkes disease'], ['hyper-IgM with immunodeficiency syndrome (HIGM)'], ['anterior pituitary aplasia'], ['HNPCC'], ['FAP']]\n",
      "[['RelA', 'p65'], ['RelB'], ['c-Rel'], ['NF-kB1/p50'], ['NF-kB2/p52']]\n",
      "[['conjugated hyperbilirubinemia'], ['coproporphyrinuria'], ['near-absent hepatic uptake of anionic diagnostics']]\n",
      "[['Agrobacterium-mediated delivery'], ['direct delivery methods'], ['methods using plant artificial chromosomes'], ['site-directed plasmid mutagenesis'], ['combined use of Red/ET recombination and unique restriction site elimination'], ['Bacterial artificial chromosomes (BACs)'], ['direct in vitro transposition of viral genomes with a BAC cassette, and subsequent recovery in Escherichia coli'], ['transformation-competent artificial chromosome (TAC)-based acceptor vector, by exploiting the CreloxP recombination system and homing endonucleases']]\n",
      "[['AzgA'], ['Fcy21p']]\n",
      "[['GDNF', 'glial cell-line-derived neurotrophic factor'], ['ARTN', 'artemin'], ['NTN', 'neurturin'], ['PSPN', 'persephin']]\n",
      "[['primaquine'], ['pamaquine'], ['chloroquine'], ['fava beans'], ['sulfonamides'], ['antibiotics'], ['henna']]\n",
      "[['I137M'], ['p.W1095X, c.3284G>A'], ['R27H'], ['E901K'], ['G1743R'], ['V728I'], ['N1443S'], ['E1152X'], ['c.664C>T; p.Arg222X'], ['Ala2>Thr, Ala735'], ['Ala735>Thr'], ['Val1340>Ile'], ['IVS18-1G>A'], ['E1784K (14x)'], ['F861WfsX90 (11x)'], ['D356N (8x)'], ['G1408R (7x)'], ['G400A'], ['H558R'], ['W822X'], ['Q55X'], ['V95I'], ['A1649V'], ['delF1617'], ['c.4810+3_4810+6dupGGGT'], ['K1527R'], ['A1569P'], ['R367H'], ['A735V'], ['R1192Q'], ['D1795'], ['p.I848fs'], ['p.R965C'], ['p.1876insM'], ['R1232W/T1620M']]\n",
      "[['Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.'], ['Pharmacological interventions for smoking cessation: an overview and network meta-analysis'], ['Effectiveness and cost-effectiveness of computer and other electronic aids for smoking cessation: a systematic review and network meta-analysis.'], ['Smoking cessation interventions in COPD: a network meta-analysis of randomised trials.']]\n",
      "[['Fanconi anemia'], ['Dyskeratosis congenita'], ['Diamond-Blackfan anemia'], ['Shwachman-Diamond syndrome']]\n",
      "[['Enterococcus faecium'], ['Staphylococcus aureus'], ['Klebsiella pneumoniae'], ['Acinetobacter baumannii'], ['Pseudomonas aeruginosa'], ['Enterobacter species']]\n",
      "[['OXA-48'], ['KPC'], ['VIM'], ['NDM'], ['IMP'], ['SME'], ['NMC'], ['GES'], ['IMI'], ['MBL']]\n",
      "[['excessively thickened endocardial layer with deep intertrabecular recesses'], ['ratio of non-compacted to compacted myocardium >2'], ['heart failure'], ['syncope'], ['ventricular arrhythmias'], ['stroke'], ['Pulmonary hypertension'], ['complete left branch conductive block'], ['sick sinus syndrome'], ['paroxysmal supraventricular tachycardia']]\n",
      "[['Repressed regions'], ['Inactive X chromosome'], ['Centromeres']]\n",
      "[['fludarabine'], ['cytarabine'], ['amsacrine']]\n",
      "[['IKKalpha', 'IKKα', 'IKK1'], ['IKKbeta', 'IKKβ', 'IKK2'], ['IKKgamma', 'IKKγ', 'NEMO']]\n",
      "[['Genscan'], ['Glimmer'], ['Fgenesh'], ['Augustus'], ['GeneID']]\n",
      "[['HIF1-alpha'], ['c-Myc'], ['Src'], ['STAT3'], ['SIRT6'], ['NF-κB'], ['Oct1'], ['HNF4-alpha'], ['PVHL']]\n",
      "[['MIB', 'mitochondrial inter-membrane space bridging complex'], ['MINOS', 'mitochondrial inner membrane organizing system'], ['MitOS']]\n",
      "[['NF1 gene'], ['chromosome 17']]\n",
      "[['β-myosin heavy chain'], ['alpha-myosin heavy chain'], ['SR(Ca)ATPase'], ['phospholamban'], ['nucleotide-gated potassium channel 2'], ['KCNE1'], ['HCN2'], ['HCN4'], ['KCND2'], ['KCND3'], ['KCNA4']]\n",
      "[['DEEP'], ['PRISM']]\n",
      "[['phosphorylated tau'], ['beta-amyloid']]\n",
      "[['KCNJ2', 'inward rectifier potassium channel gene'], ['HERG', 'KCNH2'], ['CACNA2D1'], ['KCNQ1'], ['CACNB2b']]\n",
      "[['peritonitis postoperative'], ['pain in postherpetic neuralgia'], ['duodenal ulcer'], ['nocturnal enuresis']]\n",
      "[['otitis media'], ['deep facial pain'], ['abducens nerve paralysis']]\n",
      "[['Age'], ['NIH Stroke Scale score']]\n",
      "[['phosphoenolpyruvate-carboxykinase'], ['pyruvate kinase'], ['D1', 'deiodinase 1']]\n",
      "[['bootstrap'], ['jackknife']]\n",
      "[['Minoxidil'], ['Finasteride'], ['Laser hair comb']]\n",
      "[['orexin 1'], ['orexin 2']]\n",
      "[['Proteases'], ['Keratins'], ['Bovine serum proteins'], ['Antibodies']]\n",
      "[['developmental delay'], ['epilepsy'], ['neonatal diabetes']]\n",
      "[['NBEAL2', 'neurobeachin-like 2'], ['GATA1'], ['GFI1B']]\n",
      "[['RPS19'], ['RPS24'], ['RPS17'], ['RPL35A'], ['RPL5'], ['RPL11'], ['RPS7'], ['RPS10'], ['RPS26'], ['RPL26'], ['GATA1']]\n",
      "[['congenital sensorineural deafness'], ['goiter'], ['impaired iodide organification']]\n",
      "[['B. afzelii'], ['B. garinii'], ['B. burgdorferi ss.']]\n",
      "[['p65', 'RelA'], ['p50', 'NF-κB1']]\n",
      "[['endothelin receptor A'], ['endothelin receptor B']]\n",
      "[['proton pump inhibitors'], ['immunosoppressive drugs'], ['budesonide']]\n",
      "[['high resolution protein structure determination'], ['molecular imaging', 'single-particle imaging'], ['study of enzyme kinetics', 'time resolved protein crystallography']]\n",
      "[['protein kinase A', 'PKA'], ['protein kinase G', 'PKG'], ['Ca(2+) /calmodulin-dependent protein kinase II', 'CaMKII'], ['akt kinase', 'Akt']]\n",
      "[['type 1 diabetes'], ['stiff-person syndrome'], ['cerebellar ataxia'], ['limbic encephalitis']]\n",
      "[['Papillary thyroid carcinoma'], ['Follicular thyroid carcinoma'], ['Anaplastic thyroid carcinoma'], ['Medullary thyroid carcinoma'], ['Hürthle cell carcinoma']]\n",
      "[['pulmonic stenosis'], ['ventricular septal defect'], ['overriding aorta'], ['right ventricular hypertrophy'], ['patent foramen ovale']]\n",
      "[['MYH7'], ['c.349G>A (p.D117N) in the ZASP gene'], ['pE96K mutation'], ['mutation in the isoform-1 specific region of the DSP C-terminus']]\n",
      "[['Naïve Bayes Classifier'], ['Negatome'], ['Support Vector Machine'], ['PEWCC'], ['iPTMClust'], ['NDComplex'], ['PROCOMOSS'], ['PPI network'], ['metaPIS'], ['EPOF'], ['EAGLE'], ['NFC'], ['MCODE'], ['DPClus'], ['IPCA'], ['CPM'], ['MCL'], ['CMC'], ['SPICi'], ['Core-Attachment'], ['ProRank'], ['ClusterONE'], ['CFinder'], ['Spectral'], ['RNSC'], ['Affinity Propagation'], ['HKC'], ['NWE'], ['CP-DR'], ['Struct2net'], ['PIPE']]\n",
      "[['BETAWARE'], ['BOCTOPUS'], ['BOMP'], ['BTMX'], ['HMM-B2TMR'], ['OMPdb'], ['PRED-TMBB'], ['PROB'], ['ProfTMB'], ['PV'], ['TMB finding pipeline'], ['TMBETADISC-RBF'], ['TMBETAPRED-RBF'], ['TMBHMM'], ['TMB-Hunt', 'TMB-Hunt2'], ['TMBKNN'], ['TMBpro'], ['transFold'], ['TMBETA-NET']]\n",
      "[['lacrimal gland'], ['salivary glands'], ['thyroid'], ['tear fluid']]\n",
      "[['AFP'], ['Estriol'], ['hCG']]\n",
      "[['Elonza'], ['Caverta'], ['Zenegra-100'], ['Vega Asia'], ['Suhagra-100'], ['Vega']]\n",
      "[['Neisseria meningitidis (serogroup B)'], ['Porphyromonas gingivalis'], ['Streptococcus pneumoniae'], ['Chlamydia pneumoniae'], ['Bacillus anthracis'], ['group B streptococci'], ['Helicobacter pylori'], ['Mycobacterium tuberculosis'], ['Theileria parva'], ['Brachyspira hyodysenteriae'], ['Echinococcus granulosus'], ['Ehrlichia ruminantium'], ['Leishmania spp'], ['Rhipicephalus microplus'], ['Brucella melitensis']]\n",
      "[['3,5-diiodo-L-thyronine', 'T2'], ['GC-24'], ['CO23'], ['DITPA', '3,5-diiodothyropropionic acid'], ['GC-1'], ['Tetrac', \"3,3',5,5'-tetraiodo-thyroacetic acid\"], ['KB-2115'], ['KB-141'], ['thyronamines'], ['T4-agarose'], ['CGS 23425'], ['D-T3', \"3,3',5-triiodo-D-thyronine\"], ['3,5-T2', '3,5-diiodo-L-thyronine'], ['DIT', '3,5-diiodo-L-tyrosine'], ['MIT', '3-monoiodo-L-tyrosine'], ['triac', \"3,3',5-triiodo-thyroacetic acid\"], ['3,5-Diiodo-4-hydroxyphenylpropionic acid', 'DIHPA'], [\"3,5-Dimethyl-3'-isopropyl-L-thyronine\", 'DIMIT'], [\"3,5-diiodo-3'-isopropylthyroacetic acid\", 'IpTA2']]\n",
      "[['p53', 'TP53'], ['BRCA2'], ['NRF2'], ['BRCA1'], ['BRCT'], ['HER2', 'ERBB2', 'RPS2'], ['TOP2A'], ['TRIM22']]\n",
      "[['green fluorescent protein', 'Gfp'], ['Timer', 'DsRed1-E5'], ['red fluorescent protein', 'dsRed'], ['yellow fluorescent protein'], ['beta-phycoerythrin'], ['coral fluorescent reporter protein'], ['enhanced green fluorescent reporter protein'], ['mCherry']]\n",
      "[['Oct4', 'Oct 3/4'], ['Sox2'], ['Klf4'], ['c-Myc']]\n",
      "[['MALAT1', 'MALAT-1', 'NEAT2'], ['NEAT1'], ['H19'], ['XIST']]\n",
      "[['bortezomib'], ['vincristine'], ['doxorubicin'], ['etoposide'], ['cisplatin'], ['fludarabine'], ['SD-1029 Stat3 inhibitor'], ['pingyangmycin lipiodol emulsion']]\n",
      "[['TDP-43'], ['FUS']]\n",
      "[['traumatic brain injury (TBI)'], ['sleep apnea'], ['dementia']]\n",
      "[['Vemurafenib'], ['Dabrafenib']]\n",
      "[['myocardial fibrosis using late gadolinium enhancement'], ['J-wave on ECG'], ['Extreme left ventricular hypertrophy (>30mm)'], ['Nonsustained ventricular tachycardia'], ['Sustained ventricular tachycardia'], ['previous cardiac arrest'], ['family history of sudden cardiac death'], ['unexplained syncope'], ['hypotensive response to exercise'], ['high-risk genetic mutations']]\n",
      "[['ZEB'], ['SNAIL'], ['SIRT1'], ['EGF'], ['TGFb'], ['aPKC'], ['Par6']]\n",
      "[['recurrent hypothermia'], ['hyperhidrosis'], ['congenital agenesis of the corpus callosum']]\n",
      "[['maternal immune activation (MIA) mouse model of gestational poly(IC) exposure', 'C58/J', 'Grin1', 'Shank3-deficient mice', 'C57BL/6J', 'SYNGAP1', 'Tsc2f/-', 'MALTT', '(Dp(11)17/+)', 'NR1(neo-/-)', 'TS2-neo mouse', 'Tbx1 heterozygous (HT) mice'], ['BTBR T+tf/J (BTBR)', 'VPA600', 'ProSAP1/Shank2']]\n",
      "[['Translation of interferon stimulated mRNAs during dengue virus infection'], ['Initiation of assembly of stress granules'], ['Regulation of PMP22 mRNA which was found to affect cell proliferation in breast cancer cells'], ['Participation in several signaling pathways involved in growth, differentiation and apoptosis in human tumor cells after overexpression'], ['Limit viral replication events during Sindbis virus (SINV) infection'], ['Modulation of p53 and MDM2 activity']]\n",
      "[['H3K9me3'], ['H3K9me2'], ['H3K36me3']]\n",
      "[['TREX1'], ['RNASEH2A'], ['RNASEH2B'], ['RNASEH2C'], ['SAMHD1'], ['ADAR']]\n",
      "[['Betaproteobacteria'], ['Firmicutes'], ['Geobacter', 'Geobacteraceae', 'Geobacter uraniireducens'], ['Shewanella oneidensis'], ['Pseudomonas aeruginosa'], ['Anaeromyxobacter dehalogenans'], ['strain Rf4T']]\n",
      "[['Gene transfer with viral vectors'], ['Gene transfer with non-viral vectors'], ['Transgenesis'], ['Gene Induction'], ['Fusion of the Apolipoprotein B (ApoB) low-density lipoprotein (LDL) receptor-binding domain to a targeted protein'], ['ex vivo gene therapy'], ['Intracardiac (peripheral) administration of viral neprilysin construct'], ['Syringe-focused ultrasound device'], ['Convection-enhanced delivery'], ['Use of human adipose tissue-derived mesenchymal stem cells that secrete functional neprilysin-bound exosomes']]\n",
      "[['necroptosis'], ['apoptosis'], ['pro-survival/inflammation NF-κB activation']]\n",
      "[['UMPIRE'], ['CRUCIAL'], ['AVALON'], ['ASCOT'], ['GEMINI'], ['GEMINI-AALA'], ['JEWEL 1'], ['JEWEL 2'], ['CAPABLE54'], ['CUSP'], ['TOGETHER'], ['TIPS'], ['TIPS-2'], ['IMPACT']]\n",
      "[['Alagille syndrome'], ['spondylocostal dysostosis'], ['CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)'], ['T-cell acute lymphoblastic leukemia']]\n",
      "[['Propyltiouracil'], ['Radioiodine'], ['beta blockers'], ['thyroidectomy']]\n",
      "[['NDC1', 'TMEM48', 'NET3', 'hNDC1'], ['POM121', 'Nup121'], ['GP210', 'Nuclear pore membrane glycoprotein 210', 'Nuclear envelope pore membrane protein POM 210', 'POM210', 'Nup210'], ['TMEM33', 'DB83']]\n",
      "[['hepaCAM (hepatocyte cell adhesion molecule)'], ['RARβ(2)'], ['APC'], ['TPEF (transmembrane protein containing epidermal growth factor and follistatin domain)'], ['RASSF1A'], ['p14(ARF)'], ['p16']]\n",
      "[['WPSS'], ['SCGPred'], ['TICO'], ['GLIMMER'], ['MetWAMer'], ['WebScipio'], ['GeneSeqer'], ['SplicePredictor'], ['DGSplicer'], ['TAP'], ['GeneBuilder'], ['SeqHelp'], ['FGENE', 'FGENEH'], ['HSPL'], ['RNASPL'], ['HEXON'], ['CDSB'], ['HBR']]\n",
      "[['eFSec'], ['SBP2'], ['SECp43'], ['PSTK'], ['Sec synthase', 'Sec S', 'SLA/LP'], ['SPS2', 'SelD'], ['tRNASec'], ['SECIS element'], ['(L30)'], ['SPS1']]\n",
      "[['p16', 'p16INK4', 'p16INK4a', 'MTS1', 'CDKN2'], ['p15', 'p15INK4B'], ['p18(Ink4c)'], ['p21(Waf1/Cip1/Sdi1)'], ['p27KIP1']]\n",
      "[['juvenile hemochromatosis']]\n",
      "[['TA'], ['CG'], ['(PuPy)n'], ['GCA/TGC'], ['CTA/TAG']]\n",
      "[['Insulin Dependent Diabetes Mellitus', 'type I (insulin-dependent) diabetes mellitus (IDDM)'], [\"Grave's disease\"], ['Breast Cancer'], ['Dementia']]\n",
      "[['openness'], ['extroversion'], ['conscientiousness'], ['agreeableness'], ['neuroticism']]\n",
      "[['MEC-17'], ['SIRT2 (Sirtuin 2)'], ['HDAC6 (histone deacetylase 6)'], ['dTip60']]\n",
      "[['Chronic myelogenous leukemia (CML)'], ['Gastrointestinal stromal tumor (GIST)'], ['Dermatofibrosarcoma protuberans (DFSP)']]\n",
      "[['human APOBEC3 proteins A to H'], ['Aicardi-Goutières syndrome gene product SAMHD1']]\n",
      "[['BioCreative Meta Server'], ['BioMap'], ['eFIP', 'Extracting Functional Impact of Phosphorylation'], ['GeneView'], ['Hidden Vector State model'], ['iHop'], ['LAITOR'], ['OntoGene'], ['PIE', 'Protein interaction information extraction system'], ['PPI finder', 'Paired-PPI Finder'], ['PPInterFinder'], ['PPIs'], ['PreBind', 'Textomy'], ['STRING'], ['TafTalent'], ['PolySearch'], ['Protopia'], ['OpenDMAP'], ['HAPPI']]\n",
      "[['H3K9 trimethylation'], ['H3S10 phosphorylation'], ['H3K79 methylation'], ['H4K20 trimethylation']]\n",
      "[['Amyotrophic lateral sclerosis (ALS)'], ['frontotemporal dementia (FTD)'], [\"Alzheimer's disease\"], ['fibrosis'], ['acute myeloid leukemia']]\n",
      "[['trifluridine'], ['tipiracil']]\n",
      "[['DIO 2 Thr92Ala'], ['rs7140952']]\n",
      "[['Cognitive-behavioral treatment (CBT)', 'CBT', 'group treatment', 'manualised cognitive-behavioural therapy, FRIENDS'], ['Sertraline', 'SSRI']]\n",
      "[['icatibant'], ['ecallantide']]\n",
      "[['Skin cancer'], ['ADI prostate cancer'], ['gastric adenocarcinoma'], ['colon adenocarcinoma'], ['colitis-associated cancer (CAC)'], ['breast cancer'], ['Hodgkin lymphoma'], ['nasopharyngeal carcinoma'], ['T-cell neoplasia']]\n",
      "[['diuretic'], ['hypertension']]\n",
      "[['complex syndactyly with bony fusion involving the index'], ['polydactyly'], ['short thumb with radial clinodactyly'], ['long and ring fingers'], ['symphalangism'], ['simple syndactyly of the fourth web space'], ['intrinsic muscle anomalies'], ['extrinsic tendon insertions'], ['neurovascular bundles']]\n",
      "[['PTCH1'], ['SUFU'], ['PTEN'], ['CREBBP'], ['PTEN'], ['MYT1L'], ['NFIA'], ['NFIB'], ['TEAD1'], ['TGIF2'], ['IGF2'], ['PCDH10'], ['BMI1'], ['MYC'], ['OTX2'], ['RASSF1A'], ['HIC1'], ['CASP8']]\n",
      "[['baseball'], ['football'], ['soccer'], ['cricket'], ['hockey'], ['lacrosse']]\n",
      "[['nitric oxide'], ['urea'], ['volatile organic compounds'], ['hydrogen peroxide'], ['end products of lipid peroxidation']]\n",
      "[['G:C --> A:T transitions'], ['tandem (CC --> TT) mutations'], ['G:C --> T:A transversions'], ['A:T --> C:G mutations']]\n",
      "[['erythropoietic protoporphyria'], ['vitiligo'], ['Hailey-Hailey disease'], ['acne vulgaris'], ['polymorphic light eruption'], ['ctinic keratoses'], ['nonmelanoma skin cancer']]\n",
      "[['parkinsonism'], ['central hypoventilation'], ['depression'], ['weight loss']]\n",
      "[[\"Friedreich's ataxia (FRDA)\"], [\"Huntington's disease (HD)\"]]\n",
      "[['Bapineuzumab'], ['Solanezumab'], ['Ponezumab'], ['Gantenerumab']]\n",
      "[['Etoposide (VP-16)'], ['Teniposide (VM-26)'], ['Doxorubicin'], ['Daunorubicin'], ['Aclarubicin'], ['Mitoxantrone'], ['Amsacrine (m-AMSA)']]\n",
      "[['Honokiol'], ['Thieno[3,2-d]pyrimidines and thieno[2,3-c]pyridine'], ['Quinoline-3-carbonitrile derivatives (8-halo-4-(3-chloro-4-fluoro-phenylamino)-6-[(1H-[1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles'], ['8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-methyl-1H-imidazol-4-yl)methylamino]quinoline-3-carbonitrile; 4-alkylamino-[1,7]naphthyridine-3-carbonitrile; 1,7-naphthyridine-3-carbonitriles)'], ['Indazoles']]\n",
      "[['MutY'], ['MutM'], ['MutT']]\n",
      "[['Brain glioma progression'], ['Microarray classification'], ['Mass spectral proteomics'], ['Lymph disease classification'], [\"Parkinson's disease\"]]\n",
      "[['cell elongation'], ['GTPase'], ['cell division'], ['bacterial cytoskeleton']]\n",
      "[['prostate cancer'], ['melanoma'], ['angiosarcoma']]\n",
      "[['Insyght'], ['Genomicus'], ['Sockeye']]\n",
      "[['Aspergillus terreus'], ['Aspergillus niger'], ['Ustilago maydis']]\n",
      "[['Melanoma'], ['Leukaemia'], ['Lung Cancer'], ['Colorectal Cancer'], ['Breast Cancer'], ['Head Cancer'], ['Pancreatic Cancer'], ['Prostate tumor']]\n",
      "[['Type I (1)'], ['Type II (2)'], ['Type III (3)']]\n",
      "[['mutS'], ['mutL'], ['mutH']]\n",
      "[['mTOR'], ['Raptor'], ['mLST8/GbetaL']]\n",
      "[['mannose 6-phosphate receptors (MPRs)'], ['sortilin'], ['lysosomal integral membrane protein (LIMP-2)'], ['cation-independent mannose 6-phosphate receptor (CI-MPR)']]\n",
      "[['Ulcerative colitis'], [\"Crohn's disease\"]]\n",
      "[['dnaE'], ['polC']]\n",
      "[['serotonin'], ['norepinephrine'], ['dopamine']]\n",
      "[['Type I'], ['Type II'], ['Type III']]\n",
      "[['β-MHC'], ['HCN4'], ['KCND2/3'], ['SERCA'], ['TRbeta1'], ['alpha-MHC']]\n",
      "[['Elevated Thyrotropin -', 'Elevated TSH'], ['Low FT4', 'Low Thyroxine'], ['Growth Hormone deficiency', 'GHD'], ['Calcitonin deficiency'], ['Elevated Prolactin'], ['Elevated Cortisol'], ['Elevated Oxytocin', 'Elevated OT'], ['Elevated Vasopressin', 'Elevated AVP']]\n",
      "[['electrophoresis of whole cell lysates'], ['centrifugation of whole cell lysates'], ['terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling of DNA fragments (TUNEL)'], ['in situ end labeling (ISEL) of the genomic DNA in fragmented nuclei'], ['measurement of cytosolic histone-bound DNA fragments (cell death ELISA assays)'], ['comet assay'], ['DAPI staining assay'], ['anti-DNA immunoelectron microscopy'], ['fluorescence correlation spectroscopy (FCS)']]\n",
      "[['APOBEC3G'], ['APOBEC3F'], ['APOBEC3DE'], ['APOBEC3A'], ['APOBEC3H haplotypes II, V, and VII']]\n",
      "[['15q11-13 deletions of paternal origin'], ['maternal chromosome 15 uniparental disomy'], ['rare imprinting mutations'], ['monoallelic expression of the paternal alleles']]\n",
      "[['fdfBLAST'], ['FusionDB'], ['InPrePPI', 'Integrated method for Prediction of Protein-Protein Interactions'], ['MosaicFinder'], ['Phydbac2'], ['PLEX'], ['Predictome'], ['Rosetta Stone method'], ['STRING']]\n",
      "[['short circadian period'], ['abnormal entrainment to light cycles'], ['potentiated resetting responses to light'], ['REM sleep amount'], ['NREM sleep architecture'], ['effects on cell adhesion'], ['effects on cell migration'], ['timing of sleep']]\n",
      "[['breast cancer'], ['colon cancer']]\n",
      "[['5-azacytidine', '5-aza-CR', 'Vidaza®'], ['5-azadeoxycytidine', '5-aza-CdR', 'Dacogen®', \"5-aza-2'-deoxycytidine\", 'Decitabine'], ['5-azacytosine', 'ZCyt'], ['5-fluorodeoxycytidine', 'FdC'], ['5,6-dihydro-5-azacytosine', 'DZCyt'], [\"4'-thio-2'-deoxycytidine\"], ['hydralazine'], ['2-(1H)-pyrimidinone riboside', 'zebularine'], ['2-(1H)-pyrimidinone', 'zebularine aglycon'], ['procaine'], ['procainamide'], ['RSC133'], ['Psammaplin A']]\n",
      "[['Histone 3 lysine 4 mono-methylation (H3K4me1)'], ['Histone 3 lysine 4 di-methylation (H3K4me2)']]\n",
      "[['SAGA complex'], ['TREX-2 complex']]\n",
      "[['Upf1p'], ['Nmd2p'], ['Upf3p']]\n",
      "[['H4K20 monomethylation'], ['H3K4 monomethylation']]\n",
      "[['radiotherapy'], ['chemotherapy']]\n",
      "[['COL5A1'], ['COL5A2']]\n",
      "[['Age'], ['Blood pressure'], ['Clinical features'], ['Duration of symptoms'], ['Diabetes']]\n",
      "[['scoliosis'], ['dural ectasia'], ['pectus excavatum and carinatum'], ['arachnodactyly'], ['otto pelvis', 'protrusio acetabuli'], ['dolichostenomelia'], ['ligamentous laxity']]\n",
      "[['p38alpha', 'p38α'], ['p38beta', 'p38β'], ['p38gamma', 'p38γ'], ['p38delta', 'p38δ']]\n",
      "[['Skin reactions'], ['Somnolence', 'drowsiness', 'sedation', 'lassitude'], ['Dizziness'], ['hyperactivity'], ['defiance'], ['irritability'], ['agitation'], ['aggression'], ['explosive outbursts'], ['oppositional behavior'], ['malaise']]\n",
      "[['Gata4'], ['Mef2c'], ['Tbx5']]\n",
      "[['T68'], ['S19'], ['S33/35']]\n",
      "[['GC skew analysis'], ['Z curve analysis'], ['comparative genomics'], ['dnaA gene location'], ['localization of dnaA binding sites (DnaA boxes)'], ['localization of CtrA binding sites'], ['localization of IHF binding sites'], ['localization of cell division cycle (cdc6) gene'], ['localization of other boundary genes'], ['localization of other consensus origin recognition box (ORB) sequences'], ['the gene order around the ori'], ['gene distribution in leading versus lagging strand']]\n",
      "[['type 1 diabetes'], ['seropositive rheumatoid arthritis'], ['systemic lupus erythematosus'], ['Hashimoto thyroiditis'], [\"Wegener's granulomatosis (granulomatosis with polyangiitis)\"]]\n",
      "[['adipose tissue'], ['fibrotic tissue']]\n",
      "[['H3K27ac enrichment'], ['H3K27me3 depletion']]\n",
      "[['LINE-1', 'L1'], ['Alu'], ['SVA']]\n",
      "[['Red cell aplasia'], ['Congenital anomalies'], ['Predisposition to cancer']]\n",
      "[['NELF'], ['DSIF']]\n",
      "[['congenital abnormalities'], ['defective haemopoiesis'], ['increased risk of malignancies'], ['cellular hypersensitivity to DNA crosslinking agents']]\n",
      "[['bile acide sequestrant'], ['ferrous sulphate'], ['sucralfate'], ['Calcium carbonate'], ['aluminium-containing antacids'], ['raloxifene'], ['proton pump inhibithors'], ['sevelamer'], ['chromium picolinate']]\n",
      "[['nucleotide excision repair (NER)'], ['transcription-coupled repair (TCR)'], ['suppression of illegitimate recombination']]\n",
      "[['CSBB-ConeExclusion'], ['HADDOCK'], ['ZDOCK'], ['GalaxyDock'], ['PHASE'], ['DockRank'], ['HotLig'], ['SOL'], ['AutodockVina'], ['DockoMatic'], ['DockTrina'], ['CAVITY'], ['LiGenDock'], ['DOCK'], ['DISCORE']]\n",
      "[['NBEAL2'], ['GFI1B'], ['GATA1']]\n",
      "[['RyR2-G230C'], ['RyR2-S4153R'], ['RyR2-V2475F'], ['RyR2-R2474S'], ['RyR2-N2386I'], ['RyR2-L433P'], ['RyR2-E189D'], ['RyR2-R4497C (RyR2-R4496C in the mouse)'], ['RyR2-V2306I,'], ['RyR2-P4902L'], ['RyR2-R4959Q'], ['RyR2-S2246L'], ['RyR2-N4104K']]\n",
      "[['Leukopenia'], ['paresthesia'], ['psoriasis'], ['alopecia'], ['hemolysis'], ['pancreatitis'], ['liver toxicity'], ['pericarditis']]\n",
      "[['miR-1'], ['miR-133'], ['miR-208a'], ['miR-206'], ['miR-494'], ['miR-146a'], ['miR-222'], ['miR-21'], ['miR-221'], ['miR-20a'], ['miR-133a'], ['miR-133b'], ['miR-23'], ['miR-107'], ['miR-181']]\n",
      "[['Cyclosporine A'], ['Atractyloside'], ['N-metyl-4-isoleucine-cyclosporine', 'NIM811'], ['Sanglifehrin A'], ['TRO-19622']]\n",
      "[['Spirochete Treponema denticola'], ['Clostridium perfringens'], ['Clostridium ghonii'], ['Clostridium sordellii'], ['Eubacterium tenue'], ['Bacteroides sp'], ['Vibrio'], ['Sphingomonas'], ['Afipia'], ['Curtobacterium'], ['Microbacterium'], ['Agromyces']]\n",
      "[['Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSC) transplantation'], ['Administration of 7-nitroindazole  (neuronal nitric oxide synthase inhibitor)'], ['Administration of Memantine  (un-competitive inhibitor of N-methyl-D-aspartate receptors)'], ['Administration glycogen synthase kinase-3  (GSK-3) inhibitors'], ['Administration of M1 muscarinic agonists such as AF150(S) and AF267B']]\n",
      "[['Mediator of RNA polymerase II transcription subunit 7'], ['Mediator of RNA polymerase II transcription subunit 14'], ['Mediator of RNA polymerase II transcription subunit 17'], ['Mediator of RNA polymerase II transcription subunit 23'], ['Mediator of RNA polymerase II transcription subunit 26'], ['Mediator of RNA polymerase II transcription subunit 27'], ['Mediator of RNA polymerase II transcription subunit 24']]\n",
      "[['subunit 6 of ATP synthase', 'ATPase-6'], ['mitochondrial II and III subunits of cytochrome-c oxidase'], ['NADH dehydrogenase subunit 3', 'ND3']]\n",
      "[['LMO2-C'], ['Gfi-1b'], ['MeCP1 complex'], ['ACF/WCRF complex'], ['FOG-1'], ['TAL-1'], ['Ldb-1']]\n",
      "[['amoxicillin'], ['metronidazole'], ['claritromycin'], ['Proton pump inhibithors'], ['rifabutin'], ['Eudragit L100']]\n",
      "[['alkaline phosphatase'], ['carbonic anhydrase'], ['gremlin-1'], ['fetuin A'], ['midkine'], ['annexin A1'], ['annexin A2'], ['collagen α1'], ['casein kinase II'], ['secreted frizzled related protein 4'], ['Phex'], ['asporin'], ['follistatin'], ['erbB-3'], ['LRP5'], ['noggin']]\n",
      "[['CT cisternography', 'CTC'], ['three-dimensional constructive interference in steady state', '3D-CISS']]\n",
      "[['LaTcOm'], ['%MinMax'], ['PAUSE'], ['Sherlocc'], ['Sliding Window', 'RiboTempo']]\n",
      "[['ophthalmoplegia'], ['ataxia'], ['confusion']]\n",
      "[['Ryanodine Receptor type 1', 'RyR1'], ['Ryanodine Receptor type 2', 'RyR2'], ['Ryanodine Receptor type 3', 'RyR3']]\n",
      "[['Protein Phosphatase 1', 'PP1'], ['Protein phosphatase 2A', 'PP2A'], ['Protein Phosphatase 2C', 'PP2C'], ['Protein Phosphatase 2B', 'PP2B']]\n",
      "[['AATAAA'], ['AAUAAA']]\n",
      "[['negative inotropism'], ['negative chronotropy']]\n",
      "[['They represent chemical functions valid not only for the existing bounds but also for unknown molecules.'], ['Due their simplicity they are proper for large scale virtual screening'], ['They are comprehensive and editable, so by changing chemical feature contains information can be easily trace back.']]\n",
      "[['Enistein'], ['ACE inhibitors']]\n"
     ]
    }
   ],
   "source": [
    "for sample in data['questions']:\n",
    "    if sample['type'] == 'list':\n",
    "        print (sample['exact_answer'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Exact answer in snippet checking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def getInSnippetRatio(q_type, data, answer_type='exact_answer'):\n",
    "    poor_match = []\n",
    "    in_snippet_lst = []\n",
    "    for sample in data['questions']:\n",
    "        if sample['type'] == q_type:\n",
    "            answer_snippet = []\n",
    "            for snippet in sample['snippets']:\n",
    "                answer_snippet.append(snippet['text']) \n",
    "            answer_snippet = '\\n'.join(answer_snippet)\n",
    "            answer_lst = sample[answer_type]\n",
    "            for answer in answer_lst:\n",
    "                in_snippet = False\n",
    "                if isinstance(answer, list):\n",
    "                    for ans in answer:\n",
    "                        if ans.lower() in answer_snippet.lower():\n",
    "                            in_snippet = True\n",
    "                else:\n",
    "                    in_snippet = answer.lower() in answer_snippet.lower()\n",
    "                if not in_snippet:\n",
    "                    poor_match.append((sample['body'], answer_snippet, answer_lst))\n",
    "                    break\n",
    "            in_snippet_lst.append(in_snippet)\n",
    "    print (sum(in_snippet_lst), len(in_snippet_lst), sum(in_snippet_lst)/len(in_snippet_lst))\n",
    "    return poor_match"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 58,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "320 486 0.6584362139917695\n",
      "216 413 0.5230024213075061\n"
     ]
    }
   ],
   "source": [
    "factoid_pmatch = getInSnippetRatio('factoid', data)\n",
    "list_pmatch = getInSnippetRatio('list', data)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Poor matches case study"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "metadata": {
    "collapsed": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('Which thyroid hormone transporter is implicated in thyroid hormone resistance syndrome?',\n",
       "  'Hemizygous MCT8 mutations in males cause severe psychomotor retardation, known as the Allan-Herndon-Dudley syndrome (AHDS), and abnormal serum TH levels. AHDS thus represents a type of TH resistance caused by a defect in cellular TH transport.\\n One of them, caused by mutations in the TH cell-membrane transporter MCT8, produces severe psychomotor defects.\\n Three syndromes, in which resistance to hormone action is respectively due to mutations in the gene encoding for thyroid hormone receptor TRβ, impaired T4 and T3 transport, and impaired conversion of T4 to T3 mediated by deiodinases.\\nOne, producing severe psychomotor defects in > 100 males from 26 families, is caused by mutations in the cell-membrane transporter of TH, MCT8;',\n",
       "  ['TH monocarboxylate transporter 8 (MCT8) mutation is implicated in the TH resistance syndrome']),\n",
       " ('Which is the protein that is encoded by the gene GLT8D1?',\n",
       "  '',\n",
       "  [['glycosyltransferase 8 domain containing 1']]),\n",
       " ('What is the meaning of the acronym \"TAILS\" used in protein N-terminomics?',\n",
       "  '. It is important to identify what proteins are substrates of proteases and where their cleavage sites are so as to reveal the molecular mechanisms and specificity of signaling. \\nIt is important to identify what proteins are substrates of proteases and where their cleavage sites are so as to reveal the molecular mechanisms and specificity of signaling.\\nanalysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence.\\nSeveral approaches to studying proteolytic activity as it relates to biology, pathophysiology, and drug therapy have been published, including the recently described terminal amine isotopic labeling of substrates (TAILS) strategy by Kleifeld and colleagues\\n The degradomics screen terminal amine isotopic labeling of substrates (TAILS), which enriches for neo-N-terminal peptides of cleaved substrates, was used to identify 58 new native substrates in fibroblast secretomes after incubation with MT6-MMP. \\n Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment. \\nIdentification of proteolytic products and natural protein N-termini by Terminal Amine Isotopic Labeling of Substrates (TAILS).\\n Incorporating iTRAQ whole protein labeling with terminal amine isotopic labeling of substrates (iTRAQ-TAILS) to enrich the N-terminome by negative selection of the blocked mature original N-termini and neo-N-termini has many advantages. ',\n",
       "  ['TAILS: Terminal Amine Isotopic Labeling of Substrates']),\n",
       " ('Which signaling pathway does sonidegib inhibit?',\n",
       "  'The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\nDistinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. \\nWe assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.\\nAmong such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.\\nThis phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.\\nThe absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.\\nFuture studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.\\nWe assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.\\nWe assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. \\nPURPOSE: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period. \\nPURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. \\nHedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or radiation or metastatic basal cell carcinoma. \\nPURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS: Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. \\nHedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or radiation or metastatic basal cell carcinoma. \\nPURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS: Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions. \\nPURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. \\nWe assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. \\nPURPOSE: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period. \\n The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions.\\nFuture studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.  .\\nThe association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\n This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.\\nPreliminary clinical data also suggest that inhibition of the Hh pathway, alone or in combination with JAK2 inhibition, may enable disease modification in patients with MF. Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.\\nThe absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.\\nincluding one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib,\\nThe association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\nThis phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.\\nThe absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.\\nincluding one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib,\\nThe association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\nThis phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.\\nHedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.\\n The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions.\\nincluding one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib,\\nThe association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\n This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.\\n The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg ¹⁴C-sonidegib (74 kBq, 2.0 µCi) under fasting conditions.\\nincluding one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib,\\nThe association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.\\n This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.\\nHedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.',\n",
       "  [['Hedghog signalling pathway']]),\n",
       " ('In which phase of the cell cycle arrest is impaired in Fanconi anemia?',\n",
       "  \"We found that ICLs activate a branched pathway downstream of the ATR kinase: one branch depending on CHK1 activity and the other on the FANCs-RMN complex. The transient slow-down of DNA synthesis was abolished in cells lacking ATR, whereas CHK1-siRNA-treated cells, NBS1 or FA cells showed partial S-phase arrest\\nArrest of S-phase progression is impaired in Fanconi anemia cells\\nFanconi anemia (FA) is an inherited cancer-susceptibility disorder, characterized by genomic instability, hypersensitivity to DNA cross-linking agents, and a prolonged G2 phase of the cell cycle\\nWe observed a marked dose-dependent accumulation of FA cells in the G2 compartment after treatment with 4,5',8-trimethylpsoralen (Me(3)Pso) in combination with 365 nm irradiation\\nTaken together, the above data suggest that, in response to damage induced by DNA cross-linking agents, the S-phase checkpoint is inefficient in FA cells. This would lead to accumulation of secondary lesions, such as single- and double-strand breaks and gaps. The prolonged time in G2 phase seen in FA cells therefore exists in order to allow the cells to remove lesions which accumulated during the preceding abnormal S phase\\nFanconi anemia (FA) is a genetic disorder defined by cellular hypersensitivity to DNA cross-linking agents, such as mitomycin C (MMC). MMC causes increased FA cell death, chromosome breakage, and accumulation in the G2 phase of the cell cycle\\nDNA cross-linker-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function\\nCells from individuals with Fanconi anemia (FA) arrest excessively in the G2/M cell cycle compartment after exposure to low doses of DNA cross-linking agents\\nBased on these studies we conclude that the aberrant G2/M arrest that typifies the response of FA(C) cells to low doses of cross-linking agents does not represent an abnormal cell cycle response but instead represents a normal cellular response to the excessive DNA damage that results in FA(C) cells following exposure to low doses of cross-linking agents\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nArrest of S-phase progression is impaired in Fanconi anemia cells\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\\nArrest of S-phase progression is impaired in Fanconi anemia cells.\\nThe 4N cell cycle delay in Fanconi anemia reflects growth arrest in late S phase.\",\n",
       "  [['In Fanconi anemia cells, the S-phase checkpoint is inefficient.']])]"
      ]
     },
     "execution_count": 59,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "factoid_pmatch[:5]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Exact answer in snippet checking"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "170 486 0.3497942386831276\n",
      "112 413 0.2711864406779661\n"
     ]
    }
   ],
   "source": [
    "factoid_pmatch = getInSnippetRatio('factoid', data, 'ideal_answer')\n",
    "list_pmatch = getInSnippetRatio('list', data, 'ideal_answer')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def explore(data):\n",
    "    for sample in data['questions']:\n",
    "        if sample['type'] not in ['factoid', 'list']:\n",
    "            continue\n",
    "        question = sample['body']\n",
    "        answer = "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def getQAPair(data):\n",
    "    for sample in data['questions']:\n",
    "        "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1799"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(data['questions'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "14 14 14 14\n"
     ]
    }
   ],
   "source": [
    "train = [0.0178, 0.0178, 0.072, 0.177, 0.172, 0.238, 0.345, 0.419, 0.494, 0.567, 0.622, 0.645, 0.669, 0.687]\n",
    "train_best_of_n = [0.061, 0.061, 0.156, 0.175, 0.189, 0.218, 0.279, 0.336, 0.364, 0.483, 0.554, 0.587, 0.635, 0.658]\n",
    "dev = [0.014, 0.014, 0.0691, 0.103, 0.135, 0.184, 0.256, 0.296, 0.348, 0.360, 0.328, 0.291, 0.265, 0.253]\n",
    "dev_best_of_n = [0.037, 0.037, 0.113, 0.094, 0.094, 0.132, 0.150, 0.188, 0.226, 0.245, 0.245, 0.226, 0.245, 0.264]\n",
    "print (len(train), len(train_best_of_n), len(dev), len(dev_best_of_n))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "df = pd.DataFrame({'train':train, 'train_best_of_n':train_best_of_n, 'dev':dev, 'dev_best_of_n':dev_best_of_n})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAAsgAAAGoCAYAAABbtxOxAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nRERE/Px/W1B6v8drRfIAAAAASUVORK5CYII=\n",
      "text/plain": [
       "<matplotlib.figure.Figure at 0x1fcd5b16be0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import seaborn as sns\n",
    "import matplotlib.pyplot as plt\n",
    "sns.set_style(\"whitegrid\")\n",
    "\n",
    "ax = df.plot(kind='line', style=['c-', 'c--', 'g-', 'g--'], figsize=(10, 6), alpha=0.8)\n",
    "ax.set_xlabel('epoch')\n",
    "ax.set_ylabel('accuracy')\n",
    "fig = plt.gcf()\n",
    "plt.tight_layout()\n",
    "fig.savefig('trend', dpi=300)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [
    {
     "ename": "JSONDecodeError",
     "evalue": "Extra data: line 2 column 1 (char 2956)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mJSONDecodeError\u001b[0m                           Traceback (most recent call last)",
      "\u001b[1;32m<ipython-input-37-79ece7dcfc6b>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m()\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[1;32mimport\u001b[0m \u001b[0mjson\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m      2\u001b[0m \u001b[1;32mwith\u001b[0m \u001b[0mopen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m'./data/MSMarco_dev_v1.1.json'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m'r'\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mencoding\u001b[0m\u001b[1;33m=\u001b[0m\u001b[1;34m'utf-8'\u001b[0m\u001b[1;33m)\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0mf\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m----> 3\u001b[1;33m     \u001b[0mdata\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mjson\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mload\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mf\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[1;32mD:\\Users\\star\\Anaconda3\\lib\\json\\__init__.py\u001b[0m in \u001b[0;36mload\u001b[1;34m(fp, cls, object_hook, parse_float, parse_int, parse_constant, object_pairs_hook, **kw)\u001b[0m\n\u001b[0;32m    297\u001b[0m         \u001b[0mcls\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mcls\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mobject_hook\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mobject_hook\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    298\u001b[0m         \u001b[0mparse_float\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mparse_float\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mparse_int\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mparse_int\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 299\u001b[1;33m         parse_constant=parse_constant, object_pairs_hook=object_pairs_hook, **kw)\n\u001b[0m\u001b[0;32m    300\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    301\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mD:\\Users\\star\\Anaconda3\\lib\\json\\__init__.py\u001b[0m in \u001b[0;36mloads\u001b[1;34m(s, encoding, cls, object_hook, parse_float, parse_int, parse_constant, object_pairs_hook, **kw)\u001b[0m\n\u001b[0;32m    352\u001b[0m             \u001b[0mparse_int\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m \u001b[1;32mand\u001b[0m \u001b[0mparse_float\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m \u001b[1;32mand\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    353\u001b[0m             parse_constant is None and object_pairs_hook is None and not kw):\n\u001b[1;32m--> 354\u001b[1;33m         \u001b[1;32mreturn\u001b[0m \u001b[0m_default_decoder\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mdecode\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0ms\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    355\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[0mcls\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    356\u001b[0m         \u001b[0mcls\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mJSONDecoder\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32mD:\\Users\\star\\Anaconda3\\lib\\json\\decoder.py\u001b[0m in \u001b[0;36mdecode\u001b[1;34m(self, s, _w)\u001b[0m\n\u001b[0;32m    340\u001b[0m         \u001b[0mend\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0m_w\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0ms\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mend\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mend\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    341\u001b[0m         \u001b[1;32mif\u001b[0m \u001b[0mend\u001b[0m \u001b[1;33m!=\u001b[0m \u001b[0mlen\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0ms\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 342\u001b[1;33m             \u001b[1;32mraise\u001b[0m \u001b[0mJSONDecodeError\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;34m\"Extra data\"\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0ms\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mend\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    343\u001b[0m         \u001b[1;32mreturn\u001b[0m \u001b[0mobj\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    344\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;31mJSONDecodeError\u001b[0m: Extra data: line 2 column 1 (char 2956)"
     ]
    }
   ],
   "source": [
    "import json\n",
    "with open('./data/MSMarco_dev_v1.1.json', 'r', encoding='utf-8') as f:\n",
    "    data = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "import json\n",
    "import random\n",
    "import utils\n",
    "random.seed(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "def split(data):\n",
    "    train = {'questions':[]}\n",
    "    test = {'questions':[]}\n",
    "    for q in data['questions']:\n",
    "        if random.randint(1, 101) > 80:\n",
    "            test['questions'].append(q)\n",
    "        else:\n",
    "            train['questions'].append(q)\n",
    "    return train, test"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "data = json.load(open('./BioASQ-trainingDataset5b.txt', encoding='utf-8'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "train, test = split(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "duplicate snippet count: 2944\n",
      "questions count: 385\n",
      "duplicate snippet count: 643\n",
      "questions count: 99\n"
     ]
    }
   ],
   "source": [
    "a = utils.get_qa_pair(train)\n",
    "b = utils.get_qa_pair(test)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "json.dump(train, open('./5b_train', 'w'))\n",
    "json.dump(test, open('./5b_test', 'w'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "data = json.load(open('./5b_train', encoding='utf-8'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "duplicate snippet count: 2944\n",
      "questions count: 385\n"
     ]
    }
   ],
   "source": [
    "u = utils.get_qa_pair(data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "def msmarco_to_bioasq(input_path, output_path):\n",
    "    data = []\n",
    "    with open(input_path, encoding='utf-8') as f:\n",
    "        for line in f:\n",
    "            line = line.strip('\\n')\n",
    "            data.append(json.loads(line))\n",
    "\n",
    "    bioasq_data = {'questions':[]}\n",
    "    for dct in data:\n",
    "        q = {'body':'', 'snippets':[], 'type':'factoid', 'exact_answer':[]}\n",
    "        q['body'] = dct['query']\n",
    "        q['exact_answer'] = dct['answers']\n",
    "        if len(dct['answers']) == 0:\n",
    "            continue\n",
    "        selecetd = False\n",
    "        for p in dct['passages']:\n",
    "            snippet = {'text':''}\n",
    "            snippet['text'] = p['passage_text']\n",
    "            snippet['is_selected'] = p['is_selected']\n",
    "            if p['is_selected'] == 1:\n",
    "                selecetd = True\n",
    "            q['snippets'].append(snippet)\n",
    "        if selecetd:\n",
    "            bioasq_data['questions'].append(q)\n",
    "    print ('Questions number:', len(bioasq_data['questions']))\n",
    "    print ('This script will remove question that have no answer or have no selecetd passages (unselected passages will be included for questions that have at least one selecetd passage)')\n",
    "    json.dump(bioasq_data, open(output_path, 'w'))\n",
    "    print ('Completed')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Questions number: 9696\n",
      "This script will remove question that have no answer or have no selecetd passages (unselected passages will be included for questions that have at least one selecetd passage)\n",
      "Completed\n"
     ]
    }
   ],
   "source": [
    "msmarco_to_bioasq('./data/dev_v1.1.json', './data/msmarco_test.json')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Questions number: 79625\n",
      "This script will remove question that have no answer or have no selecetd passages (unselected passages will be included for questions that have at least one selecetd passage)\n",
      "Completed\n"
     ]
    }
   ],
   "source": [
    "msmarco_to_bioasq('./data/train_v1.1.json', './data/msmarco_train.json')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "9754"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(bioasq_data['questions']) # can have no selecetd passage for a question"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "10047"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(bioasq_data['questions']) # can have no answer for questions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "duplicate snippet count: 174\n",
      "questions count: 9696\n"
     ]
    }
   ],
   "source": [
    "u = utils.get_qa_pair(bioasq_data)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "data['']"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
